[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_75d1be9e-646a-4e76-9f10-ea83063ac314":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:75d1be9e-646a-4e76-9f10-ea83063ac314,\"}":101},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":37,"indexDatabases":61,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},"75d1be9e-646a-4e76-9f10-ea83063ac314","2023-12-05T07:06:15.543+00:00","2025-11-21T09:54:07.255+00:00",[],"Journal-of-Autoimmunity",{"issn":12,"title":14},{"VOID":13},"08968411",{"EN":15},"Journal of Autoimmunity","PUBLISHER","PENDING",null,0,[21,29],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"6dc081f7-79a9-45f6-8ed3-54ef5518db41","2023-05-29T10:24:14.547+00:00","2023-11-21T07:19:21.114+00:00",[],{"EN":27},"Immunology and Allergy",{},{"id":30,"createTime":31,"updateTime":32,"relativeEntities":33,"label":34,"description":36,"parentId":18,"standard":18,"scholarHubFieldId":18},"b2f3603d-283c-49e1-a8f1-01f0de24243c","2023-05-29T10:24:14.495+00:00","2023-11-21T07:19:21.118+00:00",[],{"EN":35},"Immunology",{},[38,50],{"id":39,"createTime":40,"updateTime":41,"relativeEntities":42,"slug":43,"properties":44,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":48,"url":18,"parentIds":49,"statistic":18},"62a6a690-8a43-4af0-8658-16a2818d11be","2023-05-29T12:09:27.659+00:00","2024-02-21T00:58:14.395+00:00",[],"ACADEMIC-PRESS-LTD-ELSEVIER-SCIENCE-LTD",{"title":45},{"EN":46},"ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD","AFFILIATION",7,[],{"id":51,"createTime":52,"updateTime":53,"relativeEntities":54,"slug":55,"properties":56,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":59,"url":18,"parentIds":60,"statistic":18},"9baa59fd-2797-44b1-ae61-cc362467e9d4","2023-05-29T10:24:08.911+00:00","2025-11-21T10:06:44.504+00:00",[],"Academic-Press-Inc-",{"title":57},{"EN":58},"Academic Press Inc.",15,[],[62,81],{"id":63,"indexDatabase":64,"url":78,"indexYears":18,"academicFieldIds":79,"indexDatabaseRanking":18},"d424915c-8854-4581-940d-edd31c275897",{"id":65,"createTime":66,"updateTime":67,"relativeEntities":68,"label":69,"description":71,"key":74,"publicationTags":75,"standard":18},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":70,"VI":70},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":72,"EN":73},"Cơ sở dữ liệu SCIE","SCIE database","scie",[76,77],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0896-8411",[80],"03744874-dcbd-436b-8d5c-f6fa955ce005",{"id":82,"indexDatabase":83,"url":95,"indexYears":96,"academicFieldIds":97,"indexDatabaseRanking":100},"f570d6ca-0230-47a6-9749-acf4c8b463d3",{"id":84,"createTime":85,"updateTime":86,"relativeEntities":87,"label":88,"description":90,"key":92,"publicationTags":93,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":89,"VI":89},"Scopus - Elsevier",{"EN":89,"VI":91},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[94],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21268","1988-2025",[98,99],"2e85ca04-4b9c-4f3e-be83-f6e278d9077d","e872d6d8-194c-4b83-9ea3-8b78dd28210d","SCOPUS__Q1",{"meta":102,"data":104},{"total":103},"1648",[105,242,455,567,755,902,1034,1145,1314,1432],{"id":106,"createTime":107,"updateTime":108,"relativeEntities":109,"slug":110,"properties":111,"entityType":118,"verifyStatus":119,"verifyTime":108,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":121,"fullTextUrl":18,"authors":122,"publicationType":210,"publisherRelationship":211,"citationCount":18,"citationInfo":18,"publishDate":239,"publishYear":240,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"68f05d70-5fcf-437d-974d-29e7bb374616","2024-02-06T03:20:51.587+00:00","2025-01-07T23:59:11.990+00:00",[],"A-comparative-analysis-of-disease-associated-changes-in-the-galactosylation-of-serum-IgG",{"references":112,"title":114,"doi":116},{"VOID":113},"Parekh, 1985, Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG, Nature, 316, 452, 10.1038\u002F316452a0\nRademacher, 1986, Immunoglobulin G as a glycoprotein, 51, 131\nSutton, 1983, The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G, Biochem. Soc. Trans., 11, 130, 10.1042\u002Fbst0110130\nParekh, 1988, Galactosylation of IgG-associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity, Lancet, i, 966, 10.1016\u002FS0140-6736(88)91781-3\nParekh, 1988, Age-related galactosylation of N-linked oligosaccharides of human serum IgG, J. Exp. Med., 167, 1731, 10.1084\u002Fjem.167.5.1731\nParekh, 1988, Rheumatoid arthritis as a glycosylation disorder, Brit. J. Rheum., 27, 162, 10.1093\u002Frheumatology\u002FXXVII.suppl_2.162\nNardella, 1985, Studies on the antigenic determinants in the self-association of IgG rheumatoid factor, J. Exp. Med., 154, 112, 10.1084\u002Fjem.154.1.112\nRopes, 1958, Revision of diagnostic criteria for rheumatoid arthritis, Bull. Rheum. Dis., 9, 175\nIsenberg, 1986, Haematological re-assessment of rheumatoid arthritis, Br. J. Rheum., 25, 152, 10.1093\u002Frheumatology\u002F25.2.152\nTan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002\u002Fart.1780251101\nIsenberg, 1984, An immunohistological study of secondary Sjögren's syndrome, Ann. Rheum. Dis., 43, 470, 10.1136\u002Fard.43.3.470\nBohan, 1975, Polymyositis and dermatomyositis, N. Engl. J. Med., 292, 344, 10.1056\u002FNEJM197502132920706\nMasi, 1981, Preliminary criteria for the classification of systemic sclerosis (scleroderma), Bull. Rheum. Dis., 31, 1\nBennett, 1968, 305\nAshford, 1987, The β1→2-D-xylose and α1→3-L-fucose substituted N-linked oligosaccharides from Erythrina cristagalli lectin, Eur. J. Biochem., 166, 311, 10.1111\u002Fj.1432-1033.1987.tb13516.x\nGodfrey, 1985, Simple linear regression in medical research, N. Engl. J. Med., 313, 1629, 10.1056\u002FNEJM198512263132604\nSliwinski, 1970, In vivo synthesis of IgG by rheumatoid synovium, J. Lab. Clin. Med., 76, 304\nTomana, 1988, Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases, Arthritis Rheum., 333, 10.1002\u002Fart.1780310304\nAxford, 1988, Reduced B-cell galactosyltransferase activity in rheumatoid arthritis, Lancet, ii, 1486\nRoitt, 1982, Rheumatoid arthritis, 1161\nGeysen, 1986, Peptides which mimic carbohydrate antigens, 103\nCarson, 1987, Rheumatoid factor and immune networks, Vol. 5, 109\nPekelharing, 1988, Alterations in carbohydrate composition of serum IgG from patients with rheumatoid arthritis and from pregnant women, Ann. Rheum. Dis., 47, 91, 10.1136\u002Fard.47.2.91\nvan-Eden, 1985, Arthritis induced by a T-lymphocyte clone that responds to mycobacterium tuberculosis, and to cartilage proteoglycan, 82, 5117\nInman, 1986, Electrophorectic transfer blotting analysis of immune complexes in rheumatoid arthritis, Clin. Exp. Immunol., 63, 32\nWatkins, 1973, Catabolism of human serum IgG in health, rheumatoid arthritis, and active tuberculous disease, Ann. Rheum. Dis., 32, 247, 10.1136\u002Fard.32.3.247\nIsenberg, 1987, Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram negative infections, Clin. Exp. Immunol., 67, 516\nTorisu, 1978, A new side effect of BCG immunotherapy—BCG-induced arthritis in man, Cancer Immunol. Immunother., 5, 77, 10.1007\u002FBF00199980\nForestier, 1929, Bulletin et memoires de la Societe Medicale des Hopitaux de Paris, 53, 323\nBahr, 1988, HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis, Ann. Rheum. Dis., 1989, 63\nOttenhoff, 1987, Evidence for an HLA-DR-associated immune response gene for mycobacterium tuberculosis, Lancet, ii, 310\nBahr, 1988, HLA-DR-associated isotype-specific regulation of antibody levels to mycobacteria in rheumatoid arthritis, Clin. Exp. Immunol., 72, 26\nvan Eden, 1988, Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis, Nature, 331, 171, 10.1038\u002F331171a0\nHoloshitz, 1986, T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage, Lancet, ii, 305, 10.1016\u002FS0140-6736(86)90003-6\nBurnham, 1978, Mycobacteria as a possible cause of inflammatory bowel disease, Lancet, ii, 693, 10.1016\u002FS0140-6736(78)92699-5",{"EN":115},"A comparative analysis of disease-associated changes in the galactosylation of serum IgG",{"VOID":117},"10.1016\u002F0896-8411(89)90148-0","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0896841189901480",[123,140,156,172,185,197],{"id":124,"sortIndex":125,"researcher":18,"roles":126,"affiliations":128,"properties":137},"e5510425-187a-4407-a5b0-67bc3feed508",5,[127],"AUTHOR",[129],{"id":18,"sortIndex":19,"affiliation":130,"properties":18},{"id":131,"createTime":132,"updateTime":132,"relativeEntities":133,"slug":18,"properties":134,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"25942142-1aaf-4b88-9338-985bc1a73db4","2024-02-06T03:20:51.656+00:00",[],{"title":135},{"VI":136},"Glycobiology Unit, Department of Biochemistry, University of Oxford, UK",{"title":138},{"VI":139},"Thomas Rademacher",{"id":141,"sortIndex":142,"researcher":18,"roles":143,"affiliations":144,"properties":153},"4f737f07-80c4-4ca1-a912-9ef9fd9b833d",2,[127],[145],{"id":18,"sortIndex":19,"affiliation":146,"properties":18},{"id":147,"createTime":148,"updateTime":148,"relativeEntities":149,"slug":18,"properties":150,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3ed18b8e-e0fe-4dbe-9614-b312e66ad8ec","2024-02-06T03:20:51.632+00:00",[],{"title":151},{"VI":152},"Department of Medical Microbiology, The Middlesex Hospital Medical School, London, UK",{"title":154},{"VI":155},"Graham Rook",{"id":157,"sortIndex":158,"researcher":18,"roles":159,"affiliations":160,"properties":169},"fe32f832-074a-41b7-901c-cbbc2c2fa820",1,[127],[161],{"id":18,"sortIndex":19,"affiliation":162,"properties":18},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":165,"slug":18,"properties":166,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"44897459-965a-4c79-889d-a240455333e2","2024-02-06T03:20:51.619+00:00",[],{"title":167},{"VI":168},"Department of Immunology and Rheumatology Research, The Middlesex Hospital Medical School, London, UK",{"title":170},{"VI":171},"David Isenberg",{"id":173,"sortIndex":174,"researcher":18,"roles":175,"affiliations":176,"properties":182},"b45f0f45-b7bb-4a08-810c-2fc08c66a274",4,[127],[177],{"id":18,"sortIndex":19,"affiliation":178,"properties":18},{"id":131,"createTime":132,"updateTime":132,"relativeEntities":179,"slug":18,"properties":180,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":181},{"VI":136},{"title":183},{"VI":184},"Raymond Dwek",{"id":186,"sortIndex":19,"researcher":18,"roles":187,"affiliations":188,"properties":194},"54fbf40f-9cc5-4636-a298-7fd5b535ffb2",[127],[189],{"id":18,"sortIndex":19,"affiliation":190,"properties":18},{"id":131,"createTime":132,"updateTime":132,"relativeEntities":191,"slug":18,"properties":192,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":193},{"VI":136},{"title":195},{"VI":196},"Raj Parekh",{"id":198,"sortIndex":199,"researcher":18,"roles":200,"affiliations":201,"properties":207},"f73d3299-ba4d-433f-995d-592d4cb1dde3",3,[127],[202],{"id":18,"sortIndex":19,"affiliation":203,"properties":18},{"id":163,"createTime":164,"updateTime":164,"relativeEntities":204,"slug":18,"properties":205,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":206},{"VI":168},{"title":208},{"VI":209},"Ivan Roitt","ARTICLE",{"url":121,"publisher":212,"properties":234},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":213,"slug":10,"properties":214,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":217,"manageAffiliations":218,"indexDatabases":219,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":215,"title":216},{"VOID":13},{"EN":15},[],[],[220,227],{"id":82,"indexDatabase":221,"url":95,"indexYears":96,"academicFieldIds":226,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":222,"label":223,"description":224,"key":92,"publicationTags":225,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":228,"url":78,"indexYears":18,"academicFieldIds":233,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":229,"label":230,"description":231,"key":74,"publicationTags":232,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":235,"pages":237},{"VOID":236},"2",{"VOID":238},"101-114","1989-04-01",1989,false,{"id":243,"createTime":244,"updateTime":245,"relativeEntities":246,"slug":247,"properties":248,"entityType":118,"verifyStatus":119,"verifyTime":245,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":255,"fullTextUrl":18,"authors":256,"publicationType":210,"publisherRelationship":425,"citationCount":18,"citationInfo":18,"publishDate":453,"publishYear":454,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"fb4352d6-0fdb-48a1-84a3-86ce93904a2e","2024-02-12T06:38:54.528+00:00","2024-12-07T23:59:03.377+00:00",[],"Proteomic-analyses-of-plasma-derived-exosomes-in-immunoglobulin-Ig-G4-related-disease-and-their-potential-roles-in-B-cell-differentiation-and-tissue-damage",{"references":249,"title":251,"doi":253},{"VOID":250},"Wallace, 2019, Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts, Ann. Rheumat. Dis., 78, 406, 10.1136\u002Fannrheumdis-2018-214603\nPeng, 2019, Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study, J. Intern. Med., 286, 542, 10.1111\u002Fjoim.12942\nPerugino, 2020, IgG4-related disease: an update on pathophysiology and implications for clinical care, Nat. Rev. Rheumatol., 16, 702, 10.1038\u002Fs41584-020-0500-7\nLanzillotta, 2020, Advances in the diagnosis and management of IgG4 related disease, BMJ, 369, m1067, 10.1136\u002Fbmj.m1067\nCarruthers, 2015, The diagnostic utility of serum IgG4 concentrations in IgG4-related disease, Ann. Rheumat. Dis., 74, 14, 10.1136\u002Fannrheumdis-2013-204907\nGenschmer, 2019, Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung, Cell, 176, 113, 10.1016\u002Fj.cell.2018.12.002\nMathieu, 2019, Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication, Nat. Cell Biol., 21, 9, 10.1038\u002Fs41556-018-0250-9\nGao, 2018, Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy, Sci. Transl. Med., 10, 10.1126\u002Fscitranslmed.aat0195\nGao, 2018, Tumor-derived exosomes antagonize innate antiviral immunity, Nat. Immunol., 19, 233, 10.1038\u002Fs41590-017-0043-5\nValadi, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol., 9, 654, 10.1038\u002Fncb1596\nLi, 2013, Exosomes mediate the cell-to-cell transmission of IFN-alpha-induced antiviral activity, Nat. Immunol., 14, 793, 10.1038\u002Fni.2647\nChatila, 2014, Regulatory T cells: exosomes deliver tolerance, Immunity, 41, 3, 10.1016\u002Fj.immuni.2014.07.001\nTakahashi, 2017, Exosomes maintain cellular homeostasis by excreting harmful DNA from cells, Nat. Commun., 8, 15287, 10.1038\u002Fncomms15287\nKalluri, 2020, 367\nRobbins, 2016, Regulation of chronic inflammatory and immune processes by extracellular vesicles, J. Clin. Investig., 126, 1173, 10.1172\u002FJCI81131\nWhiteside, 2016, Exosomes and tumor-mediated immune suppression, J. Clin. Investig., 126, 1216, 10.1172\u002FJCI81136\nLi, 2014, Blockade of macrophage autophagy ameliorates activated lymphocytes-derived DNA induced murine lupus possibly via inhibition of proinflammatory cytokine production, Clin. Exp. Rheumatol., 32, 705\nLee, 2016, Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response, Arthritis Res. Ther., 18, 264, 10.1186\u002Fs13075-016-1159-y\nYeh, 2015, Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling, Blood, 125, 3297, 10.1182\u002Fblood-2014-12-618470\nUmehara, 2012, Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011, Mod. Rheumatol., 22, 21, 10.3109\u002Fs10165-011-0571-z\nMuraro, 2014, Anaphylaxis: guidelines from the European Academy of Allergy and clinical Immunology, Allergy, 69, 1026, 10.1111\u002Fall.12437\nGokce, 2011, Increasing proteome coverage with offline RP HPLC coupled to online RP nanoLC-MS, J. Chromatogr. B, Anal. Technol. Biomed. Life Sci., 879, 610, 10.1016\u002Fj.jchromb.2011.01.032\nMechtcheriakova, 2012, Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer, Canc. Immunol. Immunother. : CII, 61, 1591, 10.1007\u002Fs00262-012-1255-z\nLin, 2017, Circulating plasmablasts\u002Fplasma cells: a potential biomarker for IgG4-related disease, Arthritis Res. Ther., 19, 25, 10.1186\u002Fs13075-017-1231-2\nDella-Torre, 2020, B lymphocytes directly contribute to tissue fibrosis in patients with IgG(4)-related disease, J. Allergy Clin. Immunol., 145, 968, 10.1016\u002Fj.jaci.2019.07.004\nWallace, 2015, Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations, Ann. Rheumat. Dis., 74, 190, 10.1136\u002Fannrheumdis-2014-205233\nDefendi, 2020, The immunopathology of complement proteins and innate immunity in autoimmune disease, Clin. Rev. Allergy Immunol., 58, 229, 10.1007\u002Fs12016-019-08774-5\nDijkstra, 2019, Complement activation and regulation in rheumatic disease, Semin. Immunol., 45, 101339, 10.1016\u002Fj.smim.2019.101339\nReis, 2019, New insights into the immune functions of complement, Nat. Rev. Immunol., 19, 503, 10.1038\u002Fs41577-019-0168-x\nDunkelberger, 2010, Complement and its role in innate and adaptive immune responses, Cell Res., 20, 34, 10.1038\u002Fcr.2009.139\nKhandelwal, 2016, The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21), Blood, 128, 1789, 10.1182\u002Fblood-2016-04-709634\nKremlitzka, 2016, Regulation of B cell functions by Toll-like receptors and complement, Immunol. Lett., 178, 37, 10.1016\u002Fj.imlet.2016.07.015\nWu, 2019\nConigliaro, 2019, Complement, infection, and autoimmunity, Curr. Opin. Rheumatol., 31, 532, 10.1097\u002FBOR.0000000000000633\nWang, 2018\nLiu, 2020\nFujisawa, 2021, Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney disease, Mod. Rheumatol., 31, 241, 10.1080\u002F14397595.2019.1709942\nYang, 2019, Follicular helper T cell derived exosomes promote B cell proliferation and differentiation in antibody-mediated rejection after renal transplantation, BioMed Res. Int., 2019, 6387924\nCapello, 2019, Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity, Nat. Commun., 10, 254, 10.1038\u002Fs41467-018-08109-6\nGutzeit, 1950, Exosomes derived from Burkitt's lymphoma cell lines induce proliferation, differentiation, and class-switch recombination in B cells, J. Immunol. (Baltimore, Md, 2014, 5852\nOnnis, 2018, The pro-oxidant adaptor p66SHC promotes B cell mitophagy by disrupting mitochondrial integrity and recruiting LC3-II, Autophagy, 14, 2117, 10.1080\u002F15548627.2018.1505153\nGilljam, 1950, Differential effects of reactive oxygen species on IgG versus IgM levels in TLR-stimulated B cells, J. Immunol. (Baltimore, Md, 2020, 2133\nWang, 2018, Role of complement system in patients with biopsy-proven immunoglobulin G4-related kidney disease, Hum. Pathol., 81, 220, 10.1016\u002Fj.humpath.2018.07.008\nTabeya, 2014, The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease, Mod. Rheumatol., 24, 953, 10.3109\u002F14397595.2014.882045\nChen, 2018, vol. 70, 1853\nIshiguro, 2020, vol. 72, 166",{"EN":252},"Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage",{"VOID":254},"10.1016\u002Fj.jaut.2021.102650","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841121000585",[257,275,288,305,317,339,351,364,376,389,401,413],{"id":258,"sortIndex":259,"researcher":18,"roles":260,"affiliations":261,"properties":272},"e1f8af9d-f22d-4960-ba90-287188de7c88",6,[127],[262],{"id":18,"sortIndex":19,"affiliation":263,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":267,"slug":268,"properties":269,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"009dd7c0-5741-4de7-92f7-28b4c3693b4e","2023-12-29T20:00:32.270+00:00","2025-06-11T14:06:46.798+00:00",[],"Department-of-Rheumatology-Peking-Union-Medical-College-Hospital-Chinese-Academy-of-Medical-Science-Peking-Union-Medical-College-National-Clinical-Research-Center-for-Dermatologic-and-Immunologic-Diseases-State-Key-Laboratory-of-Complex-Severe-and-Rare-Diseases-Beijing-China",{"title":270},{"VI":271},"Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China",{"title":273},{"VI":274},"Jiaxin Zhou",{"id":276,"sortIndex":277,"researcher":18,"roles":278,"affiliations":279,"properties":285},"413eb639-eb12-4813-877c-67adec8cf863",9,[127],[280],{"id":18,"sortIndex":19,"affiliation":281,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":282,"slug":268,"properties":283,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":284},{"VI":271},{"title":286},{"VI":287},"Xiaofeng Zeng",{"id":289,"sortIndex":290,"researcher":18,"roles":291,"affiliations":292,"properties":302},"606d1c25-13c0-40ae-847e-15c62fc935cf",10,[127],[293],{"id":18,"sortIndex":19,"affiliation":294,"properties":18},{"id":295,"createTime":296,"updateTime":296,"relativeEntities":297,"slug":298,"properties":299,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"901318cd-eb7b-47d6-a463-33c12cfbe513","2023-11-24T09:25:31.624+00:00",[],"State-Key-Laboratory-of-Medical-Molecular-Biology-Department-of-Immunology-Institute-of-Basic-Medical-Sciences-Chinese-Academy-of-Medical-Sciences-School-of-Basic-Medicine-Peking-Union-Medical-College-Beijing-China",{"title":300},{"VI":301},"State Key Laboratory of Medical Molecular Biology & Department of Immunology, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China",{"title":303},{"VI":304},"Wei Ge",{"id":306,"sortIndex":142,"researcher":18,"roles":307,"affiliations":308,"properties":314},"f6919463-364e-4e94-804c-9746fec1eecc",[127],[309],{"id":18,"sortIndex":19,"affiliation":310,"properties":18},{"id":295,"createTime":296,"updateTime":296,"relativeEntities":311,"slug":298,"properties":312,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":313},{"VI":301},{"title":315},{"VI":316},"Meng Pan",{"id":318,"sortIndex":19,"researcher":18,"roles":319,"affiliations":320,"properties":336},"3c4cfa71-d5a1-4492-999f-a20b3addeb6b",[127],[321,326],{"id":18,"sortIndex":19,"affiliation":322,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":323,"slug":268,"properties":324,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":325},{"VI":271},{"id":327,"sortIndex":158,"affiliation":328,"properties":335},"f30f04aa-f156-4db8-ac62-77a91e17d883",{"id":329,"createTime":330,"updateTime":330,"relativeEntities":331,"slug":18,"properties":332,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"c613a289-7e43-440a-9169-dddf6380e34c","2024-02-12T06:38:54.576+00:00",[],{"title":333},{"VI":334},"Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, Henan Province, China",{},{"title":337},{"VI":338},"Panpan Zhang",{"id":340,"sortIndex":174,"researcher":18,"roles":341,"affiliations":342,"properties":348},"6c939600-26e2-4927-af71-d74e486b2b4d",[127],[343],{"id":18,"sortIndex":19,"affiliation":344,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":345,"slug":268,"properties":346,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":347},{"VI":271},{"title":349},{"VI":350},"Jieqiong Li",{"id":352,"sortIndex":353,"researcher":18,"roles":354,"affiliations":355,"properties":361},"14b1e010-8f47-49b8-80c3-830e9985c1a3",11,[127],[356],{"id":18,"sortIndex":19,"affiliation":357,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":358,"slug":268,"properties":359,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":360},{"VI":271},{"title":362},{"VI":363},"Wen Zhang",{"id":365,"sortIndex":199,"researcher":18,"roles":366,"affiliations":367,"properties":373},"bdbc623a-2448-47d6-800e-aab59b95d3a4",[127],[368],{"id":18,"sortIndex":19,"affiliation":369,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":370,"slug":268,"properties":371,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":372},{"VI":271},{"title":374},{"VI":375},"Zheng Liu",{"id":377,"sortIndex":378,"researcher":18,"roles":379,"affiliations":380,"properties":386},"db5f051d-59b8-428b-8336-10d6244ae37f",8,[127],[381],{"id":18,"sortIndex":19,"affiliation":382,"properties":18},{"id":329,"createTime":330,"updateTime":330,"relativeEntities":383,"slug":18,"properties":384,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":385},{"VI":334},{"title":387},{"VI":388},"Shengyun Liu",{"id":390,"sortIndex":125,"researcher":18,"roles":391,"affiliations":392,"properties":398},"a87d26a3-326c-4720-8111-47132f1b5dc7",[127],[393],{"id":18,"sortIndex":19,"affiliation":394,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":395,"slug":268,"properties":396,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":397},{"VI":271},{"title":399},{"VI":400},"Linyi Peng",{"id":402,"sortIndex":158,"researcher":18,"roles":403,"affiliations":404,"properties":410},"0f4d5a4d-bbc4-4059-928a-b92a36381d74",[127],[405],{"id":18,"sortIndex":19,"affiliation":406,"properties":18},{"id":295,"createTime":296,"updateTime":296,"relativeEntities":407,"slug":298,"properties":408,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":409},{"VI":301},{"title":411},{"VI":412},"Yusheng Zhang",{"id":414,"sortIndex":48,"researcher":18,"roles":415,"affiliations":416,"properties":422},"3119c29c-0215-4d5d-a6b7-4193cc51c1df",[127],[417],{"id":18,"sortIndex":19,"affiliation":418,"properties":18},{"id":264,"createTime":265,"updateTime":266,"relativeEntities":419,"slug":268,"properties":420,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":421},{"VI":271},{"title":423},{"VI":424},"Chaojun Hu",{"url":255,"publisher":426,"properties":448},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":427,"slug":10,"properties":428,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":431,"manageAffiliations":432,"indexDatabases":433,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":429,"title":430},{"VOID":13},{"EN":15},[],[],[434,441],{"id":82,"indexDatabase":435,"url":95,"indexYears":96,"academicFieldIds":440,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":436,"label":437,"description":438,"key":92,"publicationTags":439,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":442,"url":78,"indexYears":18,"academicFieldIds":447,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":443,"label":444,"description":445,"key":74,"publicationTags":446,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":449,"pages":451},{"VOID":450},"122",{"VOID":452},"102650","2021-08-01",2021,{"id":456,"createTime":457,"updateTime":458,"relativeEntities":459,"slug":460,"properties":461,"entityType":118,"verifyStatus":119,"verifyTime":468,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":469,"fullTextUrl":18,"authors":470,"publicationType":210,"publisherRelationship":537,"citationCount":18,"citationInfo":18,"publishDate":565,"publishYear":566,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"536c569a-9994-4286-9d4d-a0fb50bcdc68","2023-12-05T23:19:49.575+00:00","2025-01-17T23:58:52.425+00:00",[],"Expression-level-of-risk-genes-of-MHC-class-II-is-a-susceptibility-factor-for-autoimmunity-New-insights",{"references":462,"title":464,"doi":466},{"VOID":463},"Fernando, 2008, Defining the role of the MHC in autoimmunity: a review and pooled analysis, PLoS Genet., 4, 10.1371\u002Fjournal.pgen.1000024\nGutierrez-Arcelus, 2016, Autoimmune diseases - connecting risk alleles with molecular traits of the immune system, Nat. Rev. Genet., 17, 160, 10.1038\u002Fnrg.2015.33\nTrowsdale, 2013, Major histocompatibility complex genomics and human disease, Annu. Rev. Genom. Hum. Genet., 14, 301, 10.1146\u002Fannurev-genom-091212-153455\nMiyadera, 2015, Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism, J. Hum. Genet., 60, 697, 10.1038\u002Fjhg.2015.100\nSeldin, 2015, The genetics of human autoimmune disease: a perspective on progress in the field and future directions, J. Autoimmun., 64, 1, 10.1016\u002Fj.jaut.2015.08.015\nWithoff, 2016, Understanding celiac disease by genomics, Trends Genet., 32, 295, 10.1016\u002Fj.tig.2016.02.003\nNoble, 2015, Immunogenetics of type 1 diabetes: a comprehensive review, J. Autoimmun., 64, 101, 10.1016\u002Fj.jaut.2015.07.014\nUnanue, 2016, The secrets of the class II MHC peptidome start to Be revealed, J. Immunol., 196, 939, 10.4049\u002Fjimmunol.1502571\nStern, 1994, Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide, Nature, 368, 215, 10.1038\u002F368215a0\nHenderson, 2007, The production and crystallization of the human leukocyte antigen class II molecules HLA-DQ2 and HLA-DQ8 complexed with deamidated gliadin peptides implicated in coeliac disease, Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 63, 1021, 10.1107\u002FS1744309107051408\nPaul, 2013, Evaluating the immunogenicity of protein drugs by applying in vitro MHC binding data and the immune epitope database and analysis resource, Clin. Dev. Immunol., 2013, 467852, 10.1155\u002F2013\u002F467852\nShao, 2017, The SysteMHC Atlas project, Nucleic Acids Res., 45\nCamarca, 2012, Repertoire of gluten peptides active in celiac disease patients: perspectives for translational therapeutic applications, Endocr. Metab. Immune Disord. Drug Targets, 12, 207, 10.2174\u002F187153012800493549\nJabri, 2017, T cells in celiac disease, J. Immunol., 198, 3005, 10.4049\u002Fjimmunol.1601693\nMolberg, 1998, Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease, Nat. Med., 4, 713, 10.1038\u002Fnm0698-713\nvan de Wal, 1998, Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity, J. Immunol., 161, 1585, 10.4049\u002Fjimmunol.161.4.1585\nVader, 2002, Specificity of tissue transglutaminase explains cereal toxicity in celiac disease, J. Exp. Med., 195, 643, 10.1084\u002Fjem.20012028\nSollid, 2012, Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules, Immunogenetics, 64, 455, 10.1007\u002Fs00251-012-0599-z\nViken, 2017, HLA class II alleles in Norwegian patients with coexisting type 1 diabetes and celiac disease, HLA, 89, 278, 10.1111\u002Ftan.12986\nCohn, 2014, Type 1 diabetes and celiac disease: clinical overlap and new insights into disease pathogenesis, Curr Diab Rep, 14, 517, 10.1007\u002Fs11892-014-0517-x\nAntvorskov, 2014, Dietary gluten and the development of type 1 diabetes, Diabetologia, 57, 1770, 10.1007\u002Fs00125-014-3265-1\nSerena, 2015, The role of gluten in celiac disease and type 1 diabetes, Nutrients, 7, 7143, 10.3390\u002Fnu7095329\nvan Lummel, 2014, Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes, Diabetes, 63, 237, 10.2337\u002Fdb12-1214\nMatzaraki, 2017, The MHC locus and genetic susceptibility to autoimmune and infectious diseases, Genome Biol., 18, 76, 10.1186\u002Fs13059-017-1207-1\nde Bakker, 2012, Interrogating the major histocompatibility complex with high-throughput genomics, Hum. Mol. Genet., 21, R29, 10.1093\u002Fhmg\u002Fdds384\nRaychaudhuri, 2012, Autoimmunity: insights from human genomics, Curr. Opin. Immunol., 24, 513, 10.1016\u002Fj.coi.2012.09.006\nJia, 2013, Imputing amino acid polymorphisms in human leukocyte antigens, PLoS One, 8\nGutierrez-Achury, 2015, Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease, Nat. Genet., 47, 577, 10.1038\u002Fng.3268\nRomanos, 2014, Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants, Gut, 63, 415, 10.1136\u002Fgutjnl-2012-304110\nLenz, 2015, Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases, Nat. Genet., 47, 1085, 10.1038\u002Fng.3379\nHu, 2015, Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk, Nat. Genet., 47, 898, 10.1038\u002Fng.3353\nHandunnetthi, 2010, Regulation of major histocompatibility complex class II gene expression, genetic variation and disease, Gene Immun., 11, 99, 10.1038\u002Fgene.2009.83\nSuzuki, 2017, Histone acetylation and the regulation of major histocompatibility class II gene expression, Adv Protein Chem. Struct. Biol., 106, 71, 10.1016\u002Fbs.apcsb.2016.08.002\nTing, 2002, Genetic control of MHC class II expression, Cell, 109, S21, 10.1016\u002FS0092-8674(02)00696-7\nReith, 2005, Regulation of MHC class II gene expression by the class II transactivator, Nat. Rev. Immunol., 5, 793, 10.1038\u002Fnri1708\nRybtsova, 2007, Transcription-coupled deposition of histone modifications during MHC class II gene activation, Nucleic Acids Res., 35, 3431, 10.1093\u002Fnar\u002Fgkm214\nCycon, 2013, Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma, Immunology, 140, 259, 10.1111\u002Fimm.12136\nGomez, 2005, X box-like sequences in the MHC class II region maintain regulatory function, J. Immunol., 175, 1030, 10.4049\u002Fjimmunol.175.2.1030\nScharer, 2015, Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment, Nucleic Acids Res., 43, 3128, 10.1093\u002Fnar\u002Fgkv182\nRaj, 2016, Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity, Elife, 5, 10.7554\u002FeLife.12089\nCuddapah, 2009, Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains, Genome Res., 19, 24, 10.1101\u002Fgr.082800.108\nKim, 2015, CTCF as a multifunctional protein in genome regulation and gene expression, Exp. Mol. Med., 47, 10.1038\u002Femm.2015.33\nMajumder, 2006, The human major histocompatibility complex class II HLA-DRB1 and HLA-DQA1 genes are separated by a CTCF-binding enhancer-blocking element, J. Biol. Chem., 281, 18435, 10.1074\u002Fjbc.M601298200\nMajumder, 2008, The insulator factor CTCF controls MHC class II gene expression and is required for the formation of long-distance chromatin interactions, J. Exp. Med., 205, 785, 10.1084\u002Fjem.20071843\nMajumder, 2010, CTCF controls expression and chromatin architecture of the human major histocompatibility complex class II locus, Mol. Cell Biol., 30, 4211, 10.1128\u002FMCB.00327-10\nOttaviani, 2012, CTCF binds to sites in the major histocompatibility complex that are rapidly reconfigured in response to interferon-gamma, Nucleic Acids Res., 40, 5262, 10.1093\u002Fnar\u002Fgks158\nMajumder, 2011, Cohesin regulates MHC class II genes through interactions with MHC class II insulators, J. Immunol., 187, 4236, 10.4049\u002Fjimmunol.1100688\nChoi, 2011, Regulation of major histocompatibility complex class II genes, Curr. Opin. Immunol., 23, 81, 10.1016\u002Fj.coi.2010.09.007\nFehrmann, 2011, Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA, PLoS Genet., 7, 10.1371\u002Fjournal.pgen.1002197\nFairfax, 2012, Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles, Nat. Genet., 44, 502, 10.1038\u002Fng.2205\nVandiedonck, 2011, Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex, Genome Res., 21, 1042, 10.1101\u002Fgr.116681.110\nLam, 2017, Unique allelic eQTL clusters in human MHC haplotypes, G3 (Bethesda), 7, 2595, 10.1534\u002Fg3.117.043828\nSchwiebert, 1997, HLA-DRA promoter polymorphism and diversity generation within the immune system, Hum. Genet., 99, 801, 10.1007\u002Fs004390050452\nFernandez, 2003, Relative quantification of HLA-DRA1 and -DQA1 expression by real-time reverse transcriptase-polymerase chain reaction (RT-PCR), Eur. J. Immunogenet., 30, 141, 10.1046\u002Fj.1365-2370.2003.00376.x\nMaffei, 1997, Polymorphism in the 5' terminal region of the mRNA of HLA-DQA1 gene: identification of four groups of transcripts and their association with polymorphism in the alpha 1 domain, Hum. Immunol., 53, 167, 10.1016\u002FS0198-8859(97)83121-7\nDel Pozzo, 1992, DNA polymorphisms in the 5'-flanking region of the HLA-DQA1 gene, Immunogenetics, 35, 176, 10.1007\u002FBF00185111\nBritten, 2009, Differential expression of HLA-DQ alleles in peripheral blood mononuclear cells: alleles associated with susceptibility to and protection from autoimmune type 1 diabetes, Int. J. Immunogenet., 36, 47, 10.1111\u002Fj.1744-313X.2008.00823.x\nMorzycka-Wroblewska, 1993, Structure and evolution of the promoter regions of the DQA genes, Immunogenetics, 37, 364, 10.1007\u002FBF00216801\nDonner, 2002, Unbalanced amounts of HLA-DQA1 allele mRNA: DQA1*03 shows high and DQA1*0501 low amounts of mRNA in heterozygous individuals, Eur. J. Immunogenet., 29, 321, 10.1046\u002Fj.1365-2370.2002.00321.x\nBeaty, 1995, Functional effects of a natural polymorphism in the transcriptional regulatory sequence of HLA-DQB1, Mol. Cell Biol., 15, 4771, 10.1128\u002FMCB.15.9.4771\nVincent, 1996, Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction, J. Immunol., 156, 603, 10.4049\u002Fjimmunol.156.2.603\nLeen, 1994, Structural and functional analysis of HLA-DR beta-promoter polymorphism and isomorphism, Hum. Immunol., 41, 112, 10.1016\u002F0198-8859(94)90003-5\nSingal, 1996, Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB1 genes, Immunogenetics, 43, 50\nSingal, 1993, Polymorphism in the upstream regulatory regions of HLA-DRB genes, Immunogenetics, 37, 143, 10.1007\u002FBF00216839\nLouis, 1993, Polymorphism in the regulatory region of HLA-DRB genes correlating with haplotype evolution, Immunogenetics, 38, 21, 10.1007\u002FBF00216386\nMaffei, 1997, Differential expression of insulin-dependent diabetes mellitus-associated HLA-DQA1 alleles in vivo, Eur. J. Immunol., 27, 1549, 10.1002\u002Feji.1830270634\nCepek, 2016, DNA methylation and mRNA expression of HLA-DQA1 alleles in type 1 diabetes mellitus, Immunology, 148, 150, 10.1111\u002Fimm.12593\nZajacova, 2015, Differences in promoter DNA methylation and mRNA expression of individual alleles of the HLA class II DQA1 gene, Immunol. Lett., 167, 147, 10.1016\u002Fj.imlet.2015.08.006\nCavalli, 2016, MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo, Proc. Natl. Acad. Sci. U S A, 113, 1363, 10.1073\u002Fpnas.1523482113\nVander Lugt, 2014, Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation, Nat. Immunol., 15, 161, 10.1038\u002Fni.2795\nHorton, 2008, Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project, Immunogenetics, 60, 1, 10.1007\u002Fs00251-007-0262-2\nInternational, 2009, Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases, Proc. Natl. Acad. Sci. U S A, 106, 18680, 10.1073\u002Fpnas.0909307106\nVader, 2003, The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses, Proc. Natl. Acad. Sci. U S A, 100, 12390, 10.1073\u002Fpnas.2135229100\nPisapia, 2016, HLA-DQ2.5 genes associated to celiac disease risk are preferentially expressed respect to non-predisposing HLA genes: implication for anti-gluten T cell response, J. Autoimmun., 70, 63, 10.1016\u002Fj.jaut.2016.03.016\nPisapia, 2013, Co-regulated expression of alpha and beta mRNAs encoding HLA-DR surface heterodimers is mediated by the MHCII RNA operon, Nucleic Acids Res., 41, 3772, 10.1093\u002Fnar\u002Fgkt059\nCorso, 2011, EBP1 and DRBP76\u002FNF90 binding proteins are included in the major histocompatibility complex class II RNA operon, Nucleic Acids Res., 39, 7263, 10.1093\u002Fnar\u002Fgkr278",{"EN":465},"Expression level of risk genes of MHC class II is a susceptibility factor for autoimmunity: New insights",{"VOID":467},"10.1016\u002Fj.jaut.2017.12.016","2025-01-17T23:58:52.424+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841117306261",[471,486,501,513,525],{"id":472,"sortIndex":158,"researcher":18,"roles":473,"affiliations":474,"properties":483},"6b1ca4ea-5b9c-445f-91af-22ea6f0424f5",[127],[475],{"id":18,"sortIndex":19,"affiliation":476,"properties":18},{"id":477,"createTime":478,"updateTime":478,"relativeEntities":479,"slug":18,"properties":480,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6b45bd52-47c5-4c39-8b34-3a079070444f","2023-12-05T23:19:49.640+00:00",[],{"title":481},{"VI":482},"Institute of Genetics and Biophysics-CNR, Via Pietro Castellino 111, 80131, Naples, Italy",{"title":484},{"VI":485},"Laura Pisapia",{"id":487,"sortIndex":142,"researcher":18,"roles":488,"affiliations":489,"properties":498},"5ab97216-40d4-4ad0-8692-4782f9196393",[127],[490],{"id":18,"sortIndex":19,"affiliation":491,"properties":18},{"id":492,"createTime":493,"updateTime":493,"relativeEntities":494,"slug":18,"properties":495,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"adaf2250-2929-4cc2-a946-b3c2cb0589f7","2023-12-05T23:19:49.617+00:00",[],{"title":496},{"VI":497},"Institute of Protein Biochemistry-CNR, Via Pietro Castellino 111, 80131, Naples, Italy",{"title":499},{"VI":500},"Stefania Picascia",{"id":502,"sortIndex":199,"researcher":18,"roles":503,"affiliations":504,"properties":510},"d72c1c61-a63d-4209-b750-7d335ffa1470",[127],[505],{"id":18,"sortIndex":19,"affiliation":506,"properties":18},{"id":477,"createTime":478,"updateTime":478,"relativeEntities":507,"slug":18,"properties":508,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":509},{"VI":482},{"title":511},{"VI":512},"Maria Strazzullo",{"id":514,"sortIndex":19,"researcher":18,"roles":515,"affiliations":516,"properties":522},"439b4820-ebd6-422d-a56a-95833f08aa38",[127],[517],{"id":18,"sortIndex":19,"affiliation":518,"properties":18},{"id":492,"createTime":493,"updateTime":493,"relativeEntities":519,"slug":18,"properties":520,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":521},{"VI":497},{"title":523},{"VI":524},"Carmen Gianfrani",{"id":526,"sortIndex":174,"researcher":18,"roles":527,"affiliations":528,"properties":534},"b1f9c766-527d-49ea-b898-bfc38aa828a6",[127],[529],{"id":18,"sortIndex":19,"affiliation":530,"properties":18},{"id":477,"createTime":478,"updateTime":478,"relativeEntities":531,"slug":18,"properties":532,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":533},{"VI":482},{"title":535},{"VI":536},"Giovanna Del Pozzo",{"url":469,"publisher":538,"properties":560},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":539,"slug":10,"properties":540,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":543,"manageAffiliations":544,"indexDatabases":545,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":541,"title":542},{"VOID":13},{"EN":15},[],[],[546,553],{"id":82,"indexDatabase":547,"url":95,"indexYears":96,"academicFieldIds":552,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":548,"label":549,"description":550,"key":92,"publicationTags":551,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":554,"url":78,"indexYears":18,"academicFieldIds":559,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":555,"label":556,"description":557,"key":74,"publicationTags":558,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":561,"pages":563},{"VOID":562},"89",{"VOID":564},"1-10","2018-05-01",2018,{"id":568,"createTime":569,"updateTime":570,"relativeEntities":571,"slug":572,"properties":573,"entityType":118,"verifyStatus":119,"verifyTime":570,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":580,"fullTextUrl":18,"authors":581,"publicationType":210,"publisherRelationship":725,"citationCount":18,"citationInfo":18,"publishDate":753,"publishYear":754,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"d1f1ce89-b5ac-4f47-9b70-fca65279917c","2024-01-14T10:01:35.642+00:00","2025-01-14T23:58:39.752+00:00",[],"The-protease-cathepsin-L-regulates-Th17-cell-differentiation",{"references":574,"title":576,"doi":578},{"VOID":575},"Harrington, 2005, Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, Nat. Immunol., 6, 1123, 10.1038\u002Fni1254\nPark, 2005, A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nat. Immunol., 6, 1133, 10.1038\u002Fni1261\nBettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038\u002Fnature04753\nMangan, 2006, Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, 441, 231, 10.1038\u002Fnature04754\nZhou, 2007, IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways, Nat. Immunol., 8, 967, 10.1038\u002Fni1488\nDurant, 2010, Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis, Immunity, 32, 605, 10.1016\u002Fj.immuni.2010.05.003\nIvanov, 2006, The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells, Cell, 126, 1121, 10.1016\u002Fj.cell.2006.07.035\nMcGeachy, 2009, The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo, Nat. Immunol., 10, 314, 10.1038\u002Fni.1698\nCiofani, 2012, A validated regulatory network for Th17 cell specification, Cell, 151, 289, 10.1016\u002Fj.cell.2012.09.016\nYosef, 2013, Dynamic regulatory network controlling TH17 cell differentiation, Nature, 496, 461, 10.1038\u002Fnature11981\nGong, 2011, Critical role of serpinB1 in regulating inflammatory responses in pulmonary influenza infection, J. Infect. Dis., 204, 592, 10.1093\u002Finfdis\u002Fjir352\nZhao, 2014, SerpinB1 regulates homeostatic expansion of IL-17+ gammadelta and CD4+ Th17 cells, J. Leukoc. Biol., 95, 521, 10.1189\u002Fjlb.0613331\nBenarafa, 2007, The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection, J. Exp. Med., 204, 1901, 10.1084\u002Fjem.20070494\nBuhling, 2011, Gene targeting of the cysteine peptidase cathepsin H impairs lung surfactant in mice, PloS one, 6, e26247, 10.1371\u002Fjournal.pone.0026247\nLee, 2012, Synthesis and evaluation of aza-peptidyl inhibitors of the lysosomal asparaginyl endopeptidase, legumain, Bioorg. Med. Chem. Lett., 22, 1340, 10.1016\u002Fj.bmcl.2011.12.079\nGreenbaum, 2000, Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools, Chem. Biol., 7, 569, 10.1016\u002FS1074-5521(00)00014-4\nShi, 2000, Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages, J. Exp. Med., 191, 1177, 10.1084\u002Fjem.191.7.1177\nZhou, 2008, TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function, Nature, 453, 236, 10.1038\u002Fnature06878\nBarrett, 1982, L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L, Biochem. J., 201, 189, 10.1042\u002Fbj2010189\nCooley, 2001, The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites, Biochemistry, 40, 15762, 10.1021\u002Fbi0113925\nSilverman, 2001, The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature, J. Biol. Chem., 276, 33293, 10.1074\u002Fjbc.R100016200\nReiser, 2010, Specialized roles for cysteine cathepsins in health and disease, J. Clin. Invest., 120, 3421, 10.1172\u002FJCI42918\nGettins, 2002, Serpin structure, mechanism, and function, Chem. Rev., 102, 4751, 10.1021\u002Fcr010170+\nNakagawa, 1999, The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation, Immunol. Rev., 172, 121, 10.1111\u002Fj.1600-065X.1999.tb01361.x\nDrake, 1996, Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts, J. Biol. Chem., 271, 12511, 10.1074\u002Fjbc.271.21.12511\nKatunuma, 1999, Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo, FEBS Lett., 458, 6, 10.1016\u002FS0014-5793(99)01107-2\nYasuma, 1998, Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption, J. Med. Chem., 41, 4301, 10.1021\u002Fjm9803065\nLiszewski, 2013, Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation, Immunity, 39, 1143, 10.1016\u002Fj.immuni.2013.10.018\nTuomela, 2012, Identification of early gene expression changes during human Th17 cell differentiation, Blood, 119, e151, 10.1182\u002Fblood-2012-01-407528\nShirahama-Noda, 2003, Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice, J. Biol. Chem., 278, 33194, 10.1074\u002Fjbc.M302742200\nMaehr, 2005, Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice, J. Immunol., 174, 7066, 10.4049\u002Fjimmunol.174.11.7066",{"EN":577},"The protease cathepsin L regulates Th17 cell differentiation",{"VOID":579},"10.1016\u002Fj.jaut.2015.08.006","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS089684111530024X",[582,599,614,641,653,665,677,696],{"id":583,"sortIndex":199,"researcher":18,"roles":584,"affiliations":585,"properties":596},"e2fd42aa-db5e-4409-8fcd-3c24b5825128",[127],[586],{"id":18,"sortIndex":19,"affiliation":587,"properties":18},{"id":588,"createTime":589,"updateTime":590,"relativeEntities":591,"slug":592,"properties":593,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"af37a608-9bb2-4408-b98a-ebc2d9920bc8","2023-12-13T07:41:41.398+00:00","2024-10-14T00:39:16.394+00:00",[],"Department-of-Biochemistry-and-Molecular-Biology-Monash-University-Clayton-VIC-3800-Australia",{"title":594},{"VI":595},"Department of Biochemistry and Molecular Biology, Monash University, Clayton VIC 3800, Australia",{"title":597},{"VI":598},"Poh Chee Ong",{"id":600,"sortIndex":142,"researcher":18,"roles":601,"affiliations":602,"properties":611},"d25b82ab-f3c0-4832-85c5-f64b2e9e98fe",[127],[603],{"id":18,"sortIndex":19,"affiliation":604,"properties":18},{"id":605,"createTime":606,"updateTime":606,"relativeEntities":607,"slug":18,"properties":608,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"503c4901-4ae5-4055-bda4-cd4550843e76","2024-01-14T17:44:22.120+00:00",[],{"title":609},{"VI":610},"Department of Periodontics, University of Illinois at Chicago, Chicago, IL 60612, USA",{"title":612},{"VI":613},"Richard Swanson",{"id":615,"sortIndex":19,"researcher":18,"roles":616,"affiliations":617,"properties":638},"7ec2766a-e418-48bf-9978-605e34d73f9a",[127],[618,626],{"id":18,"sortIndex":19,"affiliation":619,"properties":18},{"id":620,"createTime":621,"updateTime":621,"relativeEntities":622,"slug":18,"properties":623,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"351c24c2-f70b-4501-a9ed-5020f38a5b70","2023-12-02T15:54:21.916+00:00",[],{"title":624},{"VI":625},"Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA",{"id":627,"sortIndex":158,"affiliation":628,"properties":637},"89853291-90af-404d-a19c-ae6aad3a79b7",{"id":629,"createTime":630,"updateTime":631,"relativeEntities":632,"slug":633,"properties":634,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0ae27b6f-1654-4f5e-b1fb-0778fc35497b","2024-02-08T15:11:34.677+00:00","2025-06-11T23:46:48.357+00:00",[],"Department-of-Pediatrics-Harvard-Medical-School-Boston-MA-02115-USA",{"title":635},{"VI":636},"Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA",{},{"title":639},{"VI":640},"Lifei Hou",{"id":642,"sortIndex":259,"researcher":18,"roles":643,"affiliations":644,"properties":650},"f2f28ee7-a180-4ede-a370-2a32695792d3",[127],[645],{"id":18,"sortIndex":19,"affiliation":646,"properties":18},{"id":605,"createTime":606,"updateTime":606,"relativeEntities":647,"slug":18,"properties":648,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":649},{"VI":610},{"title":651},{"VI":652},"Steven T. Olson",{"id":654,"sortIndex":174,"researcher":18,"roles":655,"affiliations":656,"properties":662},"aee9fb9c-d39f-4321-88d8-cadd5e5d95bc",[127],[657],{"id":18,"sortIndex":19,"affiliation":658,"properties":18},{"id":588,"createTime":589,"updateTime":590,"relativeEntities":659,"slug":592,"properties":660,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":661},{"VI":595},{"title":663},{"VI":664},"Robert N. Pike",{"id":666,"sortIndex":158,"researcher":18,"roles":667,"affiliations":668,"properties":674},"8b671d89-a4f9-41f7-a78d-615874d1fa62",[127],[669],{"id":18,"sortIndex":19,"affiliation":670,"properties":18},{"id":620,"createTime":621,"updateTime":621,"relativeEntities":671,"slug":18,"properties":672,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":673},{"VI":625},{"title":675},{"VI":676},"Jessica Cooley",{"id":678,"sortIndex":125,"researcher":18,"roles":679,"affiliations":680,"properties":693},"e03e02a1-c879-4802-87b7-8988ee18d698",[127],[681],{"id":682,"sortIndex":19,"affiliation":683,"properties":690},"2cb2efed-9e39-405d-87e1-4075566f62ff",{"id":684,"createTime":685,"updateTime":685,"relativeEntities":686,"slug":18,"properties":687,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"910a49f9-8875-4451-851a-92ae9a819155","2024-01-28T14:47:24.999+00:00",[],{"title":688},{"VI":689},"Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, 94305, United States",{"title":691},{"VI":692},"Department of Pathology, Stanford University School of Medicine, Palo Alto, CA 94305, USA",{"title":694},{"VI":695},"Matthew Bogyo",{"id":697,"sortIndex":48,"researcher":18,"roles":698,"affiliations":699,"properties":722},"a15d5d88-1f52-4c73-85b8-c6612946f609",[127],[700,705,715],{"id":18,"sortIndex":19,"affiliation":701,"properties":18},{"id":620,"createTime":621,"updateTime":621,"relativeEntities":702,"slug":18,"properties":703,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":704},{"VI":625},{"id":706,"sortIndex":158,"affiliation":707,"properties":714},"b59fb579-0392-4f77-b58b-23a48720310a",{"id":708,"createTime":709,"updateTime":709,"relativeEntities":710,"slug":18,"properties":711,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"aa0a8191-3acb-4118-b1af-bbe9174e2306","2024-01-14T12:57:48.928+00:00",[],{"title":712},{"VI":713},"Division of Hematology\u002FOncology, Boston Children’s Hospital, Boston, MA 02115, USA",{},{"id":716,"sortIndex":142,"affiliation":717,"properties":721},"1bd13346-93ec-4b80-8e77-1306619c8210",{"id":629,"createTime":630,"updateTime":631,"relativeEntities":718,"slug":633,"properties":719,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":720},{"VI":636},{},{"title":723},{"VI":724},"Eileen Remold-O’Donnell",{"url":580,"publisher":726,"properties":748},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":727,"slug":10,"properties":728,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":731,"manageAffiliations":732,"indexDatabases":733,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":729,"title":730},{"VOID":13},{"EN":15},[],[],[734,741],{"id":82,"indexDatabase":735,"url":95,"indexYears":96,"academicFieldIds":740,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":736,"label":737,"description":738,"key":92,"publicationTags":739,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":742,"url":78,"indexYears":18,"academicFieldIds":747,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":743,"label":744,"description":745,"key":74,"publicationTags":746,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":749,"pages":751},{"VOID":750},"65",{"VOID":752},"56-63","2015-12-01",2015,{"id":756,"createTime":757,"updateTime":758,"relativeEntities":759,"slug":760,"properties":761,"entityType":118,"verifyStatus":119,"verifyTime":758,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":768,"fullTextUrl":18,"authors":769,"publicationType":210,"publisherRelationship":872,"citationCount":18,"citationInfo":18,"publishDate":900,"publishYear":901,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"bfce5f93-4110-4ca4-8d9d-d2660ab81c08","2023-12-28T23:05:11.635+00:00","2024-12-22T23:58:33.988+00:00",[],"Two-discreet-subsets-of-CD8-T-cells-modulate-PLP91-110-induced-experimental-autoimmune-encephalomyelitis-in-HLA-DR3-transgenic-mice",{"references":762,"title":764,"doi":766},{"VOID":763},"Libbey, 2010, Studies in the modulation of experimental autoimmune encephalomyelitis, J Neuroimmune Pharmacol, 5, 168, 10.1007\u002Fs11481-010-9215-x\nSospedra, 2005, Immunology of multiple sclerosis, Annu Rev Immunol, 23, 683, 10.1146\u002Fannurev.immunol.23.021704.115707\nTsunoda, 1996, Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus, J Neuropathol Exp Neurol, 55, 673, 10.1097\u002F00005072-199606000-00001\nLuckey, 2011, Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice, J Autoimmun, 37, 122, 10.1016\u002Fj.jaut.2011.05.001\nMangalam, 2004, Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice, EurJ Immunol, 34, 280, 10.1002\u002Feji.200324597\nMangalam, 2008, HLA class II transgenic mice mimic human inflammatory diseases, Adv Immunol, 97, 65, 10.1016\u002FS0065-2776(08)00002-3\nTsuchida, 1994, Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides, Proc Natl Acad Sci U S A, 91, 10859, 10.1073\u002Fpnas.91.23.10859\nJurewicz, 1998, MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes, J Immunol, 160, 3056\nBiddison, 1997, Chemokine and matrix metalloproteinase secretion by myelin proteolipid protein-specific CD8+ T cells: potential roles in inflammation, J Immunol, 158, 3046\nLucchinetti, 1997, The controversy surrounding the pathogenesis of the multiple sclerosis lesion, Proc Mayo Clin, 72, 665, 10.1016\u002FS0025-6196(11)63576-3\nBugawan, 2000, High-resolution HLA class I typing in the CEPH families: analysis of linkage disequilibrium among HLA loci, Tissue Antigens, 56, 392, 10.1034\u002Fj.1399-0039.2000.560502.x\nBabbe, 2000, Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction, J Exp Med, 192, 393, 10.1084\u002Fjem.192.3.393\nGay, 1997, The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. identification and characterization of the primary demyelinating lesion, Brain, 120, 1461, 10.1093\u002Fbrain\u002F120.8.1461\nLassmann, 1998, Neuropathology in multiple sclerosis: new concepts, Mult Scler, 4, 93, 10.1177\u002F135245859800400301\nShresta, 1998, How do cytotoxic lymphocytes kill their targets?, Curr Opin Immunol, 10, 581, 10.1016\u002FS0952-7915(98)80227-6\nTrapani, 2000, Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo, Curr Opin Immunol, 12, 323, 10.1016\u002FS0952-7915(00)00094-7\nHuseby, 2001, A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis, J Exp Med, 194, 669, 10.1084\u002Fjem.194.5.669\nSun, 2001, Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL\u002F6 mice, J Immunol, 166, 7579, 10.4049\u002Fjimmunol.166.12.7579\nAristimuno, 2010, IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study, Clin Immunol, 134, 148, 10.1016\u002Fj.clim.2009.09.008\nAristimuno, 2008, Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after i.v. methyl-prednisolone for multiple sclerosis relapse, J Neuroimmunol, 204, 131, 10.1016\u002Fj.jneuroim.2008.08.009\nFletcher, 2010, T cells in multiple sclerosis and experimental autoimmune encephalomyelitis, Clin Exp Immunol, 162, 1, 10.1111\u002Fj.1365-2249.2010.04143.x\nTennakoon, 2006, Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis, J Immunol, 176, 7119, 10.4049\u002Fjimmunol.176.11.7119\nZozulya, 2008, The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation, Hum Immunol, 69, 797, 10.1016\u002Fj.humimm.2008.07.014\nJiang, 1995, Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TCR: a role of the Qa-1 molecule, Immunity, 2, 185, 10.1016\u002FS1074-7613(95)80079-4\nJiang, 1992, Role of CD8+ T cells in murine experimental allergic encephalomyelitis, Science New York NY, 256, 1213, 10.1126\u002Fscience.256.5060.1213\nKoller, 1990, Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells, Science New York NY, 248, 1227, 10.1126\u002Fscience.2112266\nDas, 2000, Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis, Hum Immunol, 61, 279, 10.1016\u002FS0198-8859(99)00135-4\nMangalam, 2008, HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma, J Immunol, 180, 7747, 10.4049\u002Fjimmunol.180.11.7747\nPavelko, 2003, Interleukin-6 protects anterior horn neurons from lethal virus-induced injury, J Neurosci, 23, 481, 10.1523\u002FJNEUROSCI.23-02-00481.2003\nInaba, 1992, Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\u002Fmacrophage colony-stimulating factor, J Exp Med, 176, 1693, 10.1084\u002Fjem.176.6.1693\nGiri, 2004, 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase, J Neurosci, 24, 479, 10.1523\u002FJNEUROSCI.4288-03.2004\nChen, 2009, Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms, Eur J Immunol, 39, 3423, 10.1002\u002Feji.200939441\nCortesini, 2001, CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity, Immunol Rev, 182, 201, 10.1034\u002Fj.1600-065X.2001.1820116.x\nCosmi, 2003, Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes, Blood, 102, 4107, 10.1182\u002Fblood-2003-04-1320\nNajafian, 2003, Regulatory functions of CD8+CD28- T cells in an autoimmune disease model, J Clin Invest, 112, 1037, 10.1172\u002FJCI17935\nRifa'i, 2004, Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis, J Exp Med, 200, 1123, 10.1084\u002Fjem.20040395\nRifa'i, 2008, CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabetaTCR interaction and become IL-10-producing active regulatory cells, Int Immol, 20, 937, 10.1093\u002Fintimm\u002Fdxn052\nGoverman, 2005, The role of CD8(+) T cells in multiple sclerosis and its animal models, Curr Drug Targets, 4, 239, 10.2174\u002F1568010053586264\nWhitacre, 2004, Spotlight on CD8 T cells in MS, Blood, 103, 3999, 10.1182\u002Fblood-2004-03-1148\nKoh, 1992, Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-\u002F- mice, Science New York NY, 256, 1210, 10.1126\u002Fscience.256.5060.1210\nAbdul-Majid, 2003, Comparing the pathogenesis of experimental autoimmune encephalomyelitis in CD4-\u002F- and CD8-\u002F- DBA\u002F1 mice defines qualitative roles of different T cell subsets, J Neuroimmunol, 141, 10, 10.1016\u002FS0165-5728(03)00210-8\nDittel, 2008, CD4 T cells: balancing the coming and going of autoimmune-mediated inflammation in the CNS, Brain Behav Immun, 22, 421, 10.1016\u002Fj.bbi.2007.11.010\nGoverman, 2011, Immune tolerance in multiple sclerosis, Immunol Rev, 241, 228, 10.1111\u002Fj.1600-065X.2011.01016.x\nKlebb, 1996, Interleukin-2 is indispensable for development of immunological self-tolerance, Clin Immunol Immunopathol, 81, 282, 10.1006\u002Fclin.1996.0190\nFilaci, 2011, CD8(+) T regulatory\u002Fsuppressor cells and their relationships with autoreactivity and autoimmunity, Autoimmunity, 44, 51, 10.3109\u002F08916931003782171\nShi, 2009, Human CD8+CXCR3+ T cells have the same function as murine CD8+CD122+ Treg, Eur J Immunol, 39, 2106, 10.1002\u002Feji.200939314\nShi, 2008, Importance of CD80\u002FCD86-CD28 interactions in the recognition of target cells by CD8+CD122+ regulatory T cells, Immunology, 124, 121, 10.1111\u002Fj.1365-2567.2007.02747.x\nEndharti, 2005, Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells, J Immunol, 175, 7093, 10.4049\u002Fjimmunol.175.11.7093\nWillenborg, 1999, IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide, J Immunol, 163, 5278\nLee, 2008, Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis, J Immunol, 180, 825, 10.4049\u002Fjimmunol.180.2.825\nWillenborg, 1996, IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis, J Immunol, 157, 3223\nZozulya, 2009, The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE, Eur J Immunol, 39, 1536, 10.1002\u002Feji.200839165",{"EN":765},"Two discreet subsets of CD8 T cells modulate PLP91–110 induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice",{"VOID":767},"10.1016\u002Fj.jaut.2012.02.004","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841112000273",[770,785,797,812,824,848,860],{"id":771,"sortIndex":158,"researcher":18,"roles":772,"affiliations":773,"properties":782},"ade728ec-51ef-4c1b-999c-bdc13f79f1e5",[127],[774],{"id":18,"sortIndex":19,"affiliation":775,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":778,"slug":18,"properties":779,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"9b71bb62-2318-43cc-ae3d-cd12c95bb01d","2023-12-28T23:05:11.701+00:00",[],{"title":780},{"VI":781},"Department of Immunology, Mayo Clinic College of Medicine, 200, 1st Street SW, Rochester, MN 55905, USA",{"title":783},{"VI":784},"David Luckey",{"id":786,"sortIndex":174,"researcher":18,"roles":787,"affiliations":788,"properties":794},"009667cf-c630-48c8-bc85-3675948d05c3",[127],[789],{"id":18,"sortIndex":19,"affiliation":790,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":791,"slug":18,"properties":792,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":793},{"VI":781},{"title":795},{"VI":796},"Larry R. Pease",{"id":798,"sortIndex":142,"researcher":18,"roles":799,"affiliations":800,"properties":809},"4dde6b49-3114-41f8-ade8-c360bf418e1d",[127],[801],{"id":18,"sortIndex":19,"affiliation":802,"properties":18},{"id":803,"createTime":804,"updateTime":804,"relativeEntities":805,"slug":18,"properties":806,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2e9e7bd3-111a-457a-81d8-26d2450a2dce","2023-12-28T23:05:11.673+00:00",[],{"title":807},{"VI":808},"Department of Experimental pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA",{"title":810},{"VI":811},"Shailendra Giri",{"id":813,"sortIndex":259,"researcher":18,"roles":814,"affiliations":815,"properties":821},"89f3cc9d-259e-48d4-9535-6efa19f40c93",[127],[816],{"id":18,"sortIndex":19,"affiliation":817,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":818,"slug":18,"properties":819,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":820},{"VI":781},{"title":822},{"VI":823},"Chella S. David",{"id":825,"sortIndex":125,"researcher":18,"roles":826,"affiliations":827,"properties":845},"8e1e7227-422c-4866-ab42-1afc87d1fd9b",[127],[828,840],{"id":829,"sortIndex":158,"affiliation":830,"properties":839},"a7280aa9-367f-40cd-acab-a999740c0125",{"id":831,"createTime":832,"updateTime":833,"relativeEntities":834,"slug":835,"properties":836,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a5917a50-a785-4d3c-916e-be45e9fe3f34","2023-12-08T00:26:08.058+00:00","2024-09-23T00:34:58.969+00:00",[],"Department-of-Neurology-Mayo-Clinic-College-of-Medicine-Rochester-MN-55905-USA",{"title":837},{"VI":838},"Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA",{},{"id":18,"sortIndex":19,"affiliation":841,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":842,"slug":18,"properties":843,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":844},{"VI":781},{"title":846},{"VI":847},"Moses Rodriguez",{"id":849,"sortIndex":199,"researcher":18,"roles":850,"affiliations":851,"properties":857},"221d6f85-3f38-4fa3-946a-8fdf04f34f09",[127],[852],{"id":18,"sortIndex":19,"affiliation":853,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":854,"slug":18,"properties":855,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":856},{"VI":781},{"title":858},{"VI":859},"Michele Smart",{"id":861,"sortIndex":19,"researcher":18,"roles":862,"affiliations":863,"properties":869},"9725efdb-e057-4dfe-9ded-c2edd4fb586a",[127],[864],{"id":18,"sortIndex":19,"affiliation":865,"properties":18},{"id":776,"createTime":777,"updateTime":777,"relativeEntities":866,"slug":18,"properties":867,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":868},{"VI":781},{"title":870},{"VI":871},"Ashutosh K. Mangalam",{"url":768,"publisher":873,"properties":895},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":874,"slug":10,"properties":875,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":878,"manageAffiliations":879,"indexDatabases":880,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":876,"title":877},{"VOID":13},{"EN":15},[],[],[881,888],{"id":82,"indexDatabase":882,"url":95,"indexYears":96,"academicFieldIds":887,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":883,"label":884,"description":885,"key":92,"publicationTags":886,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":889,"url":78,"indexYears":18,"academicFieldIds":894,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":890,"label":891,"description":892,"key":74,"publicationTags":893,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":896,"pages":898},{"VOID":897},"38",{"VOID":899},"344-353","2012-06-01",2012,{"id":903,"createTime":904,"updateTime":905,"relativeEntities":906,"slug":907,"properties":908,"entityType":118,"verifyStatus":119,"verifyTime":905,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":915,"fullTextUrl":18,"authors":916,"publicationType":210,"publisherRelationship":1006,"citationCount":18,"citationInfo":18,"publishDate":1033,"publishYear":240,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"dc53b04f-8fbb-4a54-8da6-e8429acd9d03","2024-01-13T23:44:40.020+00:00","2024-12-22T23:58:33.956+00:00",[],"IgG-class-anti-cardiolipin-antibody-as-a-possible-marker-for-evaluating-fetal-risk-in-patients-with-systemic-lupus-erythematosus",{"references":909,"title":911,"doi":913},{"VOID":910},"Wallace, 1987, Lupus pregnancy and neonatal lupus, 565\nDrue, 1985, Fetal loss in systemic lupus: association with anticardiolipin antibodies, J. Obstet. Gynaecol., 5, 207, 10.3109\u002F01443618509067758\nLockshin, 1985, Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with lupus erythmatosus, N. Engl. J. Med., 313, 152, 10.1056\u002FNEJM198507183130304\nDerksen, 1985, Lupus anticoagulant: revival of an old phenomenon, Clin. Exp. Rheumatol., 3, 349\nLockshin, 1985, Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient, Arthritis Rheum., 28, 58, 10.1002\u002Fart.1780280110\nMintz, 1986, Prospective study of pregnancy in systemic lupus erythematosus. Results of a multidisciplinary approach, J. Rheumatol., 13, 732\nHarris, 1986, Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin test, Arch. Intern. Med., 146, 2153, 10.1001\u002Farchinte.146.11.2153\nLockshin, 1987, Antibody to cardiolipin lupus anticoagulant and fetal death, J. Rheumatol., 14, 259\nTan, 1982, The 1982 revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002\u002Fart.1780251101\nKoike, 1984, Anti-phospholipid antibodies and biological false positive serological tests for syphilis in patients with systemic lupus erythematosus, Clin. Exp. Immunol., 56, 193\nProctor, 1961, The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies, Am. J. Clin. Pathol., 36, 212, 10.1093\u002Fajcp\u002F36.3.212\nColaco, 1987, Cross-reaction with anti-single stranded DNA activity, Clin. Exp. Immunol., 68, 313\nBranch, 1987, Association of lupus anticoagulant with antibody against phosphatidyl serine, Clin. Immunol. Immunopathol., 42, 63, 10.1016\u002F0090-1229(87)90173-5\nIchikawa, 1988, Monoclonal hybridoma anti-cardiolipin antibodies from SLE mice, Clin. Exp. Immunol., 74, 110\nCarreras, 1981, Arterial thrombosis intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacyclin formation, Lancet, 1, 244, 10.1016\u002FS0140-6736(81)92087-0\nCarreras, 1982, ‘Lupus’ anticoagulant and thrombosis-possible role of inhibition of prostacyclin formation, Thromb. Haematstas., 48, 38, 10.1055\u002Fs-0038-1657211\nDe Wolf, 1982, Decidual vasculopathy and extensive placental infarction in a patient with repeated thrombotic accidents, recurrent fetal loss and a lupus anticoagulant, Am. J. Obstet. Gynecol., 77, 829, 10.1016\u002FS0002-9378(16)32527-3\nSanfelippo, 1982, Prekallikrein inhibition associated with the lupus anticoagulant, a mechanism of thrombosis, Am. J. Clin. Pathol., 77, 275, 10.1093\u002Fajcp\u002F77.3.275\nLubbe, 1983, Fetal survival after prednisolone suppression of maternal lupus-anticoagulant, Lancet, 1, 1361, 10.1016\u002FS0140-6736(83)92141-4\nBranch, 1985, Obstetric complications associated with lupus anticoagulant, N. Engl. J. Med., 313, 1322, 10.1056\u002FNEJM198511213132104\nStafford-Brady, 1988, Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant, Arch. Intern. Med., 148, 1647, 10.1001\u002Farchinte.148.7.1647",{"EN":912},"IgG class anti-cardiolipin antibody as a possible marker for evaluating fetal risk in patients with systemic lupus erythematosus",{"VOID":914},"10.1016\u002F0896-8411(89)90010-3","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F0896841189900103",[917,934,946,958,970,982,994],{"id":918,"sortIndex":199,"researcher":18,"roles":919,"affiliations":920,"properties":931},"a0d0f722-52ad-48d5-88d5-77bb14695aca",[127],[921],{"id":18,"sortIndex":19,"affiliation":922,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":926,"slug":927,"properties":928,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"3f2ea26d-603e-45ed-a504-9e4e0d208cb3","2024-02-02T09:40:46.679+00:00","2024-11-27T23:42:30.943+00:00",[],"Second-Department-of-Internal-Medicine-Chiba-University-School-of-Medicine-Chiba-Japan-",{"title":929},{"VI":930},"Second Department of Internal Medicine, Chiba University School of Medicine, Chiba, Japan.",{"title":932},{"VI":933},"Akito Tsutsumi",{"id":935,"sortIndex":142,"researcher":18,"roles":936,"affiliations":937,"properties":943},"6c34a67c-9d41-40c3-8c20-6a57efca7d2c",[127],[938],{"id":18,"sortIndex":19,"affiliation":939,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":940,"slug":927,"properties":941,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":942},{"VI":930},{"title":944},{"VI":945},"Kenji Ichikawa",{"id":947,"sortIndex":174,"researcher":18,"roles":948,"affiliations":949,"properties":955},"9b039ebc-e1ec-4000-b29b-b371937ae851",[127],[950],{"id":18,"sortIndex":19,"affiliation":951,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":952,"slug":927,"properties":953,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":954},{"VI":930},{"title":956},{"VI":957},"Katsuhiko Takabayashi",{"id":959,"sortIndex":125,"researcher":18,"roles":960,"affiliations":961,"properties":967},"2c662d9c-1d1a-45fa-b3b0-73b95f8b3cc8",[127],[962],{"id":18,"sortIndex":19,"affiliation":963,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":964,"slug":927,"properties":965,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":966},{"VI":930},{"title":968},{"VI":969},"Hisao Tomioka",{"id":971,"sortIndex":259,"researcher":18,"roles":972,"affiliations":973,"properties":979},"6503b2f0-4f16-4dad-b454-1905e12c2297",[127],[974],{"id":18,"sortIndex":19,"affiliation":975,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":976,"slug":927,"properties":977,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":978},{"VI":930},{"title":980},{"VI":981},"Sho Yoshida",{"id":983,"sortIndex":19,"researcher":18,"roles":984,"affiliations":985,"properties":991},"6ad43bdc-a0f1-483f-9569-ebd601d9d61e",[127],[986],{"id":18,"sortIndex":19,"affiliation":987,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":988,"slug":927,"properties":989,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":990},{"VI":930},{"title":992},{"VI":993},"Kaoru Shimada",{"id":995,"sortIndex":158,"researcher":18,"roles":996,"affiliations":997,"properties":1003},"6b188d4e-f992-464e-b018-b35d9f560dbf",[127],[998],{"id":18,"sortIndex":19,"affiliation":999,"properties":18},{"id":923,"createTime":924,"updateTime":925,"relativeEntities":1000,"slug":927,"properties":1001,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1002},{"VI":930},{"title":1004},{"VI":1005},"Takao Koike",{"url":915,"publisher":1007,"properties":1029},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1008,"slug":10,"properties":1009,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1012,"manageAffiliations":1013,"indexDatabases":1014,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1010,"title":1011},{"VOID":13},{"EN":15},[],[],[1015,1022],{"id":82,"indexDatabase":1016,"url":95,"indexYears":96,"academicFieldIds":1021,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1017,"label":1018,"description":1019,"key":92,"publicationTags":1020,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":1023,"url":78,"indexYears":18,"academicFieldIds":1028,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":1024,"label":1025,"description":1026,"key":74,"publicationTags":1027,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":1030,"pages":1031},{"VOID":236},{"VOID":1032},"843-849","1989-12-01",{"id":1035,"createTime":1036,"updateTime":1037,"relativeEntities":1038,"slug":1039,"properties":1040,"entityType":118,"verifyStatus":119,"verifyTime":1037,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":142,"primaryUrl":1047,"fullTextUrl":18,"authors":1048,"publicationType":210,"publisherRelationship":1115,"citationCount":18,"citationInfo":18,"publishDate":1143,"publishYear":1144,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"ec9c54a3-8316-414c-ae9e-adc5c6801a5e","2024-01-01T09:44:23.836+00:00","2025-02-15T23:57:37.916+00:00",[],"The-antiphospholipid-syndrome-in-patients-with-systemic-lupus-erythematosus",{"references":1041,"title":1043,"doi":1045},{"VOID":1042},"Gomez-Puerta, 2014, Diagnosis and classification of the antiphospholipid syndrome, J. Autoimmun., 48–49, 20, 10.1016\u002Fj.jaut.2014.01.006\nHughes, 1983, Thrombosis, abortion, cerebral disease, and the lupus anticoagulant, Br. Med. J. Clin. Res. Ed., 287, 1088, 10.1136\u002Fbmj.287.6399.1088\nCervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum., 46, 1019, 10.1002\u002Fart.10187\nBiggioggero, 2010, The geoepidemiology of the antiphospholipid antibody syndrome, Autoimmun. Rev., 9, A299, 10.1016\u002Fj.autrev.2009.11.013\nCervera, 2008, Lessons from the “Euro-Phospholipid” project, Autoimmun. Rev., 7, 174, 10.1016\u002Fj.autrev.2007.11.011\nAppenzeller, 2011, HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies, Semin. Arthritis Rheum., 41, 517, 10.1016\u002Fj.semarthrit.2011.05.007\nTincani, 2009, Neonatal effects of maternal antiphospholipid syndrome, Curr. Rheumatol. Rep., 11, 70, 10.1007\u002Fs11926-009-0010-8\nMiyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 4, 295, 10.1111\u002Fj.1538-7836.2006.01753.x\nHughes, 1985, The anticardiolipin syndrome, Clin. Exp. Rheumatol., 3, 285\nMackworth-Young, 1989, Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder, Ann. Rheum. Dis., 48, 362, 10.1136\u002Fard.48.5.362\nAsherson, 1988, A “primary” antiphospholipid syndrome?, J. Rheumatol., 15, 1742\nMok, 2005, Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups, Arthritis Rheum., 52, 2774, 10.1002\u002Fart.21224\nTektonidou, 2009, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Rheum., 61, 29, 10.1002\u002Fart.24232\nRuiz-Irastorza, 2004, High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus, Arch. Intern Med., 164, 77, 10.1001\u002Farchinte.164.1.77\nOpatrny, 2006, Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, J. Rheumatol., 33, 2214\nGomez-Puerta, 2005, Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?, Med. Baltim., 84, 225, 10.1097\u002F01.md.0000172074.53583.ea\nMujic, 1995, Primary antiphospholipid syndrome evolving into systemic lupus erythematosus, J. Rheumatol., 22, 1589\nCervera, 2015, Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Ann. Rheum. Dis., 74, 1011, 10.1136\u002Fannrheumdis-2013-204838\nBorchers, 2010, The geoepidemiology of systemic lupus erythematosus, Autoimmun. Rev., 9, A277, 10.1016\u002Fj.autrev.2009.12.008\nReshetniak, 2003, Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up, Ter. Arkh, 75, 46\nCervera, 2003, Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients, Med. Baltim., 82, 299, 10.1097\u002F01.md.0000091181.93122.55\nWilson, 1999, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum., 42, 1309, 10.1002\u002F1529-0131(199907)42:7\u003C1309::AID-ANR1>3.0.CO;2-F\nBobba, 2007, A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?, J. Rheumatol., 34, 1522\nHochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 40, 1725, 10.1002\u002Fart.1780400928\nPiette, 1993, Exclusion criteria for primary antiphospholipid syndrome, J. Rheumatol., 20, 1802\nMeroni, 2004, Inflammatory response and the endothelium, Thromb. Res., 114, 329, 10.1016\u002Fj.thromres.2004.06.045\nRuiz-Irastorza, 2011, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, 206, 10.1177\u002F0961203310395803\nBarbhaiya, 2011, Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?, Curr. Rheumatol. Rep., 13, 59, 10.1007\u002Fs11926-010-0149-3\nForastiero, 2005, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis, J. Thromb. Haemost., 3, 1231, 10.1111\u002Fj.1538-7836.2005.01295.x\nGalli, 2007, Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, 110, 1178, 10.1182\u002Fblood-2007-01-066043\nUrbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, Lancet Neurol., 8, 998, 10.1016\u002FS1474-4422(09)70239-X\nPengo, 2010, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J. Thromb. Haemost., 8, 237, 10.1111\u002Fj.1538-7836.2009.03674.x\nGalli, 2003, Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, 102, 2717, 10.1182\u002Fblood-2002-11-3334\nGalli, 2003, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, 101, 1827, 10.1182\u002Fblood-2002-02-0441\nMartinez-Berriotxoa, 2007, Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus, Lupus, 16, 810, 10.1177\u002F0961203307083316\nErkan, 2011, Antiphospholipid syndrome clinical research task force report, Lupus, 20, 219, 10.1177\u002F0961203310395053\nNalli, 2014, Management of recurrent thrombosis in antiphospholipid syndrome, Curr. Rheumatol. Rep., 16, 405, 10.1007\u002Fs11926-013-0405-4\nUrowitz, 2016, Modified framingham risk factor score for systemic lupus erythematosus, J. Rheumatol., 43, 875, 10.3899\u002Fjrheum.150983\nOtomo, 2012, Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events, Arthritis Rheum., 64, 504, 10.1002\u002Fart.33340\nSciascia, 2013, GAPSS: the global anti-phospholipid syndrome score, Rheumatol. Oxf., 52, 1397, 10.1093\u002Frheumatology\u002Fkes388\nBarbar, 2010, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score, J. Thromb. Haemost., 8, 2450, 10.1111\u002Fj.1538-7836.2010.04044.x\nBruce, 2005, 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus, Rheumatol. Oxf., 44, 1492, 10.1093\u002Frheumatology\u002Fkei142\nCeccarelli, 2012, Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “Pros” and “Cons”, Autoimmun. Rev., 11, 568, 10.1016\u002Fj.autrev.2011.10.014\nWahl, 2000, Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis, Arch. Intern Med., 160, 2042, 10.1001\u002Farchinte.160.13.2042\nArnaud, 2014, Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis, Autoimmun. Rev., 13, 281, 10.1016\u002Fj.autrev.2013.10.014\nLeung, 2002, Mortality and malignancy in the multi-ethnic Birmingham lupus cohort aspirin use is beneficial and non-Caucasian origin is not associated with poor outcome, Rheumatology, 41, S17\nCuadrado, 2014, Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS), Rheumatol. Oxf., 53, 275, 10.1093\u002Frheumatology\u002Fket313\nRuiz-Irastorza, 2010, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann. Rheum. Dis., 69, 20, 10.1136\u002Fard.2008.101766\nJung, 2010, The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis Rheum., 62, 863, 10.1002\u002Fart.27289\nMok, 2005, Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus, J. Rheumatol., 32, 622\nBelizna, 2015, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome, Autoimmun. Rev., 14, 358, 10.1016\u002Fj.autrev.2014.12.006\nBorba, 2001, Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy, J. Rheumatol., 28, 780\nCairoli, 2012, Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect, Lupus, 21, 1178, 10.1177\u002F0961203312450084\nTam, 2000, Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus, J. Rheumatol., 27, 2142\nEspinola, 2002, Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies, Thromb. Haemost., 87, 518, 10.1055\u002Fs-0037-1613033\nDurcan, 2016, Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy, J. Rheumatol., 43, 745, 10.3899\u002Fjrheum.150437\nBroder, 2013, Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\u002For lupus anticoagulant in systemic lupus erythematosus, J. Rheumatol., 40, 30, 10.3899\u002Fjrheum.120157\nKaiser, 2009, Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort, Ann. Rheum. Dis., 68, 238, 10.1136\u002Fard.2008.093013\nRuffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, Ann. Rheum. Dis., 70, 1083, 10.1136\u002Fard.2010.142042\nDoria, 2003, Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus, Ann. Rheum. Dis., 62, 1071, 10.1136\u002Fard.62.11.1071\nHaque, 2010, Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study, J. Rheumatol., 37, 322, 10.3899\u002Fjrheum.090306\nManzi, 1999, Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus, Arthritis Rheum., 42, 51, 10.1002\u002F1529-0131(199901)42:1\u003C51::AID-ANR7>3.0.CO;2-D\nBruce, 1999, Natural history of hypercholesterolemia in systemic lupus erythematosus, J. Rheumatol., 26, 2137\nLeong, 1994, Lipid profiles in patients with systemic lupus erythematosus, J. Rheumatol., 21, 1264\nPetri, 1992, Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices, Med. Baltim., 71, 291, 10.1097\u002F00005792-199209000-00004\nZen, 2011, The kaleidoscope of glucocorticoid effects on immune system, Autoimmun. Rev., 10, 305, 10.1016\u002Fj.autrev.2010.11.009\nvan Vollenhoven, 2016, Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials, Arthritis Rheumatol., 68, 2184, 10.1002\u002Fart.39682\nArtenjak, 2012, Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review, Autoimmun. Rev., 11, 873, 10.1016\u002Fj.autrev.2012.03.002\nLateef, 2013, Managing lupus patients during pregnancy, Best. Pract. Res. Clin. Rheumatol., 27, 435, 10.1016\u002Fj.berh.2013.07.005\nDel Ross, 2013, Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study, J. Rheumatol., 40, 425, 10.3899\u002Fjrheum.120576\nFishman, 1993, Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3, J. Clin. Invest, 91, 1834, 10.1172\u002FJCI116396\nRoberge, 2012, Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis, Am. J. Perinatol., 29, 551\nRoberge, 2012, Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis, Fetal Diagn. Ther., 31, 141, 10.1159\u002F000336662\nAndreoli, 2016, EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\u002For antiphospholipid syndrome, Ann. Rheum. Dis., 10.1136\u002Fannrheumdis-2016-209770\nEmpson, 2005, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database Syst. Rev., 10.1002\u002F14651858.CD002859.pub2\nErkan, 2008, Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers, Rheumatol. Oxf., 47, iii23\nMak, 2010, Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression, Rheumatol. Oxf., 49, 281, 10.1093\u002Frheumatology\u002Fkep373\nCervera, 2009, Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients, Ann. Rheum. Dis., 68, 1428, 10.1136\u002Fard.2008.093179\nGarcía-Carrasco, 2007, Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients, Lupus, 16, 366, 10.1177\u002F0961203307077108\nNeville, 2009, Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort, Thromb. Haemost., 101, 100, 10.1160\u002FTH08-06-0384\nKearon, 2012, Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 141, e419S, 10.1378\u002Fchest.11-2301\nLes, 2012, Intensity and duration of anticoagulation therapy in antiphospholipid syndrome, Semin. Thromb. Hemost., 38, 339, 10.1055\u002Fs-0032-1304720\nMeroni, 2012, Obstetric and vascular APS: same autoantibodies but different diseases?, Lupus, 21, 708, 10.1177\u002F0961203312438116\nPengo, 2012, High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS', Autoimmun. Rev., 11, 577, 10.1016\u002Fj.autrev.2011.10.016\nOkuma, 2009, Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome, Int. J. Med. Sci., 7, 15\nGiannubilo, 2012, Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia, Curr. Med. Chem., 19, 4562, 10.2174\u002F092986712803306466\nSciascia, 2016, Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome, Rheumatol. Oxf., 55, 1726, 10.1093\u002Frheumatology\u002Fkev445\nNoel, 2015, Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome, Autoimmun. Rev., 14, 680, 10.1016\u002Fj.autrev.2015.03.007\nChighizola, 2014, New oral anticoagulants in thrombotic antiphospholipid syndrome, Lupus, 23, 1279, 10.1177\u002F0961203314540968\nCohen, 2015, Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\u002FIII clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE, Lupus, 24, 1087, 10.1177\u002F0961203315581207\nPengo, 2016, Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, 25, 301, 10.1177\u002F0961203315611495\nWu, 2014, The medical management of antiphospholipid syndrome in pregnancy: a meta-analysis, Obstet. Gynecol., 123, 178s, 10.1097\u002F01.AOG.0000447195.12926.b9\nPettila, 2002, Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin, Thromb. Haemost., 87, 182, 10.1055\u002Fs-0037-1612970\nReggia, 2014, Current treatment strategies for management of antiphospholipid syndrome, Expert Opin. Orphan Drugs, 2\nGinsberg, 2001, Use of antithrombotic agents during pregnancy, Chest, 119, 122S, 10.1378\u002Fchest.119.1_suppl.122S\nOstensen, 2006, Anti-inflammatory and immunosuppressive drugs and reproduction, Arthritis Res. Ther., 8, 209, 10.1186\u002Far1957\nBramham, 2011, First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss, Blood, 117, 6948, 10.1182\u002Fblood-2011-02-339234\nVaquero, 2001, Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin, Am. J. Reprod. Immunol., 45, 174, 10.1111\u002Fj.8755-8920.2001.450309.x\nRuffatti, 2014, Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study, Thromb. Haemost., 112, 727, 10.1160\u002FTH14-03-0191\nEriksson, 2012, Physical activity in patients with systemic lupus erythematosus and matched controls, Scand. J. Rheumatol., 41, 290, 10.3109\u002F03009742.2011.624117\nRemans, 2004, Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects, Eur. J. Clin. Nutr., 58, 839, 10.1038\u002Fsj.ejcn.1601883\nYokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016\u002FS0140-6736(07)60527-3\nWright, 2008, A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus, Ann. Rheum. Dis., 67, 841, 10.1136\u002Fard.2007.077156\nBello, 2013, Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus, Rheumatol. Int., 33, 2789, 10.1007\u002Fs00296-013-2811-3\nAgmon-Levin, 2011, Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression, Ann. Rheum. Dis., 70, 145, 10.1136\u002Fard.2010.134817\nPiantoni, 2012, Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease, Reumatismo, 64, 307, 10.4081\u002Freumatismo.2012.307\nSahebari, 2014, Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders, Lupus, 23, 1164, 10.1177\u002F0961203314540966\nReynolds, 2012, 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus, Rheumatol. Oxf., 51, 544, 10.1093\u002Frheumatology\u002Fker352\nPoole, 2006, Reduced vitamin D in acute stroke, Stroke, 37, 243, 10.1161\u002F01.STR.0000195184.24297.c1\nRavenell, 2012, Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients, Am. J. Med. Sci., 344, 268, 10.1097\u002FMAJ.0b013e31823fa7d9\nRidker, 2013, Statins: new American guidelines for prevention of cardiovascular disease, Lancet, 382, 1762, 10.1016\u002FS0140-6736(13)62388-0\nRidker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet, 373, 1175, 10.1016\u002FS0140-6736(09)60447-5\nKotyla, 2006, Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin, J. Rheumatol., 33, 2361\nRiboldi, 2005, Statins and autoimmune diseases, Lupus, 14, 765, 10.1191\u002F0961203305lu2217oa\nTang, 2011, Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis, J. Lipid Res., 52, 1023, 10.1194\u002Fjlr.M010876\nWang, 2015, Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment, Int. heart J., 56, 163, 10.1536\u002Fihj.14-245\nFerreira, 2007, Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial, Rheumatol. Oxf., 46, 1560, 10.1093\u002Frheumatology\u002Fkem186\nPlazak, 2011, Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study, Arthritis Res. Ther., 13, R117, 10.1186\u002Far3402\nSahebkar, 2016, Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials, Autoimmun. Rev., 15, 344, 10.1016\u002Fj.autrev.2015.12.007\nMok, 2011, Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial, Arthritis Care Res. Hob., 63, 875, 10.1002\u002Facr.20440\nJajoria, 2009, Statins for the treatment of antiphospholipid syndrome?, Ann. N. Y. Acad. Sci., 1173, 736, 10.1111\u002Fj.1749-6632.2009.04815.x\nSoubrier, 2013, Do all lupus patients need statins?, Jt. Bone Spine, 80, 244, 10.1016\u002Fj.jbspin.2012.08.014\nPetri, 2011, Lupus atherosclerosis prevention study (LAPS), Ann. Rheum. Dis., 70, 760, 10.1136\u002Fard.2010.136762\nBerman, 2013, Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmun. Rev., 12, 1085, 10.1016\u002Fj.autrev.2013.05.004\nSciascia, 2012, Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin. Exp. Rheumatol., 30, 409\nErkan, 2013, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis Rheum., 65, 464, 10.1002\u002Fart.37759\nBakhtar, 2014, A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab, Transplantation, 98, e17, 10.1097\u002FTP.0000000000000267\nLonze, 2014, Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg., 14, 459, 10.1111\u002Fajt.12540\nBucciarelli, 2006, Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients, Arthritis Rheum., 54, 2568, 10.1002\u002Fart.22018\nShapira, 2012, Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis Rheum., 64, 2719, 10.1002\u002Fart.34440\nCanaud, 2014, Inhibition of the mTORC pathway in the antiphospholipid syndrome, N. Engl. J. Med., 371, 303, 10.1056\u002FNEJMoa1312890\nDoria, 2006, Long-term prognosis and causes of death in systemic lupus erythematosus, Am. J. Med., 119, 700, 10.1016\u002Fj.amjmed.2005.11.034\nBertsias, 2010, EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann. Rheum. Dis., 69, 2074, 10.1136\u002Fard.2010.130476\nMoroni, 2004, Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am. J. Kidney Dis., 43, 28, 10.1053\u002Fj.ajkd.2003.09.011\nTaraborelli, 2016, The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus, Lupus, 25, 1365, 10.1177\u002F0961203316637431",{"EN":1044},"The antiphospholipid syndrome in patients with systemic lupus erythematosus",{"VOID":1046},"10.1016\u002Fj.jaut.2016.10.004","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841116302475",[1049,1064,1076,1091,1103],{"id":1050,"sortIndex":158,"researcher":18,"roles":1051,"affiliations":1052,"properties":1061},"1422e265-2e4b-49a8-b6e2-9e6d93b14a3d",[127],[1053],{"id":18,"sortIndex":19,"affiliation":1054,"properties":18},{"id":1055,"createTime":1056,"updateTime":1056,"relativeEntities":1057,"slug":18,"properties":1058,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"76bafa86-a11b-4c22-83fb-14275403256d","2024-01-01T09:44:23.852+00:00",[],{"title":1059},{"VI":1060},"Department of Clinical and Experimental Sciences, University of Brescia, Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy",{"title":1062},{"VI":1063},"Laura Andreoli",{"id":1065,"sortIndex":174,"researcher":18,"roles":1066,"affiliations":1067,"properties":1073},"1dbe7f03-d68b-4197-8bf8-3453bdcf621b",[127],[1068],{"id":18,"sortIndex":19,"affiliation":1069,"properties":18},{"id":1055,"createTime":1056,"updateTime":1056,"relativeEntities":1070,"slug":18,"properties":1071,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1072},{"VI":1060},{"title":1074},{"VI":1075},"Angela Tincani",{"id":1077,"sortIndex":199,"researcher":18,"roles":1078,"affiliations":1079,"properties":1088},"911d35e2-5a7c-4516-85c7-6e01b559fbe8",[127],[1080],{"id":18,"sortIndex":19,"affiliation":1081,"properties":18},{"id":1082,"createTime":1083,"updateTime":1083,"relativeEntities":1084,"slug":18,"properties":1085,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"998c4984-cd7d-4936-8637-8e206876f097","2023-12-17T14:52:38.005+00:00",[],{"title":1086},{"VI":1087},"Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain",{"title":1089},{"VI":1090},"Ricard Cervera",{"id":1092,"sortIndex":142,"researcher":18,"roles":1093,"affiliations":1094,"properties":1100},"0b678756-cba6-4bbc-91c9-0a54e90127f2",[127],[1095],{"id":18,"sortIndex":19,"affiliation":1096,"properties":18},{"id":1055,"createTime":1056,"updateTime":1056,"relativeEntities":1097,"slug":18,"properties":1098,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1099},{"VI":1060},{"title":1101},{"VI":1102},"Francesco Scanzi",{"id":1104,"sortIndex":19,"researcher":18,"roles":1105,"affiliations":1106,"properties":1112},"3ea91bbe-94f8-451b-8f6f-a3afd11a2c63",[127],[1107],{"id":18,"sortIndex":19,"affiliation":1108,"properties":18},{"id":1082,"createTime":1083,"updateTime":1083,"relativeEntities":1109,"slug":18,"properties":1110,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1111},{"VI":1087},{"title":1113},{"VI":1114},"Guillermo J. Pons-Estel",{"url":1047,"publisher":1116,"properties":1138},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1117,"slug":10,"properties":1118,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1121,"manageAffiliations":1122,"indexDatabases":1123,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1119,"title":1120},{"VOID":13},{"EN":15},[],[],[1124,1131],{"id":82,"indexDatabase":1125,"url":95,"indexYears":96,"academicFieldIds":1130,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1126,"label":1127,"description":1128,"key":92,"publicationTags":1129,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":1132,"url":78,"indexYears":18,"academicFieldIds":1137,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":1133,"label":1134,"description":1135,"key":74,"publicationTags":1136,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":1139,"pages":1141},{"VOID":1140},"76",{"VOID":1142},"10-20","2017-01-01",2017,{"id":1146,"createTime":1147,"updateTime":1148,"relativeEntities":1149,"slug":1150,"properties":1151,"entityType":118,"verifyStatus":119,"verifyTime":1148,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1158,"fullTextUrl":18,"authors":1159,"publicationType":210,"publisherRelationship":1284,"citationCount":18,"citationInfo":18,"publishDate":1312,"publishYear":1313,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"5d5cd5c2-9e91-4778-81cf-7b6477bd0b5d","2024-01-25T03:18:19.267+00:00","2024-09-19T23:56:14.408+00:00",[],"Astrocytic-autoantibody-of-neuromyelitis-optica-NMO-IgG-binds-to-aquaporin-4-extracellular-loops-monomers-tetramers-and-high-order-arrays",{"references":1152,"title":1154,"doi":1156},{"VOID":1153},"Lennon, 2005, IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel, J Exp Med, 202, 473, 10.1084\u002Fjem.20050304\nLennon, 2004, A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, Lancet, 364, 2106, 10.1016\u002FS0140-6736(04)17551-X\nHasegawa, 1994, Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues, J Biol Chem, 269, 5497, 10.1016\u002FS0021-9258(17)37486-0\nJung, 1994, Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance, Proc Natl Acad Sci U S A, 91, 13052, 10.1073\u002Fpnas.91.26.13052\nFurman, 2003, Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms, Proc Natl Acad Sci U S A, 100, 13609, 10.1073\u002Fpnas.2235843100\nCrane, 2009, Live cell analysis of aquaporin-4 m1\u002Fm23 interactions and regulated orthogonal array assembly in glial cells, J Biol Chem, 284, 35850, 10.1074\u002Fjbc.M109.071670\nMcKeon, 2009, Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays, Arch Neurol, 66, 1134, 10.1001\u002Farchneurol.2009.178\nWingerchuk, 2006, Revised diagnostic criteria for neuromyelitis optica, Neurology, 66, 1485, 10.1212\u002F01.wnl.0000216139.44259.74\nPolman, 2011, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, 69, 292, 10.1002\u002Fana.22366\nHinson, 2012, Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes, Proc Natl Acad Sci USA, 109, 1245, 10.1073\u002Fpnas.1109980108\nWolburg, 2011, Structure and functions of aquaporin-4-based orthogonal arrays of particles, Int Rev Cell Mol Biol, 287, 1, 10.1016\u002FB978-0-12-386043-9.00001-3\nMarnetto, 2009, Western blot analysis for the detection of serum antibodies recognizing linear aquaporin-4 epitopes in patients with neuromyelitis optica, J Neuroimmunol, 217, 74, 10.1016\u002Fj.jneuroim.2009.10.002\nNicchia, 2009, Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies, Glia, 57, 1363, 10.1002\u002Fglia.20855\nCrane, 2011, Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\u002FM23 isoforms and orthogonal arrays, J Biol Chem, 286, 16516, 10.1074\u002Fjbc.M111.227298\nSorbo, 2008, The molecular composition of square arrays, Biochemistry, 47, 2631, 10.1021\u002Fbi702146k\nKampylafka, 2011, Fine specificity of antibodies against AQP4: epitope mapping reveals intracellular epitopes, J Autoimmun, 36, 221, 10.1016\u002Fj.jaut.2011.01.004\nHinson, 2007, Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica, Neurology, 69, 2221, 10.1212\u002F01.WNL.0000289761.64862.ce\nHinson, 2008, Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2, J Exp Med, 205, 2473, 10.1084\u002Fjem.20081241\nWaters, 2012, Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays, Neurology, 78, 665, 10.1212\u002FWNL.0b013e318248dec1\nBennett, 2009, Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica, Ann Neurol, 66, 617, 10.1002\u002Fana.21802\nMader, 2010, Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica, PLoS One, 5, e10455, 10.1371\u002Fjournal.pone.0010455\nRossi, 2010, Evidences for a leaky scanning mechanism for the synthesis of the shorter M23 protein isoform of aquaporin-4: implication in orthogonal array formation and neuromyelitis optica antibody interaction, J Biol Chem, 285, 4562, 10.1074\u002Fjbc.M109.069245\nTani, 2009, Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica, J Neuroimmunol, 211, 110, 10.1016\u002Fj.jneuroim.2009.04.001\nHiroaki, 2006, Implications of the aquaporin-4 structure on array formation and cell adhesion, J Mol Biol, 355, 628, 10.1016\u002Fj.jmb.2005.10.081\nHo, 2009, Crystal structure of human aquaporin 4 at 1.8 A and its mechanism of conductance, Proc Natl Acad Sci U S A, 106, 7437, 10.1073\u002Fpnas.0902725106\nPisani, 2011, Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding, J Biol Chem, 286, 9216, 10.1074\u002Fjbc.M110.123000",{"EN":1155},"Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays",{"VOID":1157},"10.1016\u002Fj.jaut.2012.07.008","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841112001047",[1160,1195,1214,1229,1241,1253,1272],{"id":1161,"sortIndex":259,"researcher":18,"roles":1162,"affiliations":1163,"properties":1192},"9c279c5a-b898-4dea-95d7-dbaa4412e1ea",[127],[1164,1174,1182],{"id":1165,"sortIndex":158,"affiliation":1166,"properties":1173},"96f70d38-80bd-454e-88cf-c0005d5f4ef0",{"id":1167,"createTime":1168,"updateTime":1168,"relativeEntities":1169,"slug":18,"properties":1170,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7b9a9dea-52fd-4f9c-bd3d-da8b4b3a8fea","2024-01-25T03:18:19.353+00:00",[],{"title":1171},{"VI":1172},"Department of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA",{},{"id":18,"sortIndex":19,"affiliation":1175,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1178,"slug":18,"properties":1179,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2563189f-88ce-4c19-afcb-6643712bf97e","2024-01-11T19:50:57.935+00:00",[],{"title":1180},{"VI":1181},"Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA, ",{"id":1183,"sortIndex":142,"affiliation":1184,"properties":1191},"610a9110-4e1b-40cd-93d5-f033f966eef8",{"id":1185,"createTime":1186,"updateTime":1186,"relativeEntities":1187,"slug":18,"properties":1188,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7cd9509f-c11a-4dce-9687-ffe2af5ce3df","2024-01-25T03:18:19.376+00:00",[],{"title":1189},{"VI":1190},"Department of Immunology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA",{},{"title":1193},{"VI":1194},"Vanda A. Lennon",{"id":1196,"sortIndex":125,"researcher":18,"roles":1197,"affiliations":1198,"properties":1211},"fa1ce9e2-d5e3-4cb3-a275-fa88b7bcef81",[127],[1199,1204],{"id":18,"sortIndex":19,"affiliation":1200,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1201,"slug":18,"properties":1202,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1203},{"VI":1181},{"id":1205,"sortIndex":158,"affiliation":1206,"properties":1210},"50fc0881-ca30-42c8-a5a0-8586f4459a8e",{"id":1167,"createTime":1168,"updateTime":1168,"relativeEntities":1207,"slug":18,"properties":1208,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1209},{"VI":1172},{},{"title":1212},{"VI":1213},"Sean J. Pittock",{"id":1215,"sortIndex":174,"researcher":18,"roles":1216,"affiliations":1217,"properties":1226},"d1a2fd60-cbe2-4ac9-b45d-e7cd89abf490",[127],[1218],{"id":18,"sortIndex":19,"affiliation":1219,"properties":18},{"id":1220,"createTime":1221,"updateTime":1221,"relativeEntities":1222,"slug":18,"properties":1223,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a8eec298-ab82-4270-874b-802d2b7a8f65","2024-01-25T03:18:19.335+00:00",[],{"title":1224},{"VI":1225},"Institute of Pathology and Neuropathology, University of Tübingen, D-72076 Tübingen, Germany",{"title":1227},{"VI":1228},"Hartwig Wolburg",{"id":1230,"sortIndex":158,"researcher":18,"roles":1231,"affiliations":1232,"properties":1238},"0d5262f2-44f5-4f74-ad03-ba3405a9729a",[127],[1233],{"id":18,"sortIndex":19,"affiliation":1234,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1235,"slug":18,"properties":1236,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1237},{"VI":1181},{"title":1239},{"VI":1240},"James P. Fryer",{"id":1242,"sortIndex":199,"researcher":18,"roles":1243,"affiliations":1244,"properties":1250},"3d9a1d36-85b8-4d60-9843-84391e365dfb",[127],[1245],{"id":18,"sortIndex":19,"affiliation":1246,"properties":18},{"id":1220,"createTime":1221,"updateTime":1221,"relativeEntities":1247,"slug":18,"properties":1248,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1249},{"VI":1225},{"title":1251},{"VI":1252},"Petra Fallier-Becker",{"id":1254,"sortIndex":19,"researcher":18,"roles":1255,"affiliations":1256,"properties":1269},"2bd200a6-123f-434c-a546-973204601ca5",[127],[1257,1264],{"id":1258,"sortIndex":158,"affiliation":1259,"properties":1263},"e41b0b88-8d28-411d-913c-5c349e372ffb",{"id":1167,"createTime":1168,"updateTime":1168,"relativeEntities":1260,"slug":18,"properties":1261,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1262},{"VI":1172},{},{"id":18,"sortIndex":19,"affiliation":1265,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1266,"slug":18,"properties":1267,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1268},{"VI":1181},{"title":1270},{"VI":1271},"Raffaele Iorio",{"id":1273,"sortIndex":142,"researcher":18,"roles":1274,"affiliations":1275,"properties":1281},"69f16d06-2a40-4b37-9eeb-b8dbce224da3",[127],[1276],{"id":18,"sortIndex":19,"affiliation":1277,"properties":18},{"id":1176,"createTime":1177,"updateTime":1177,"relativeEntities":1278,"slug":18,"properties":1279,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1280},{"VI":1181},{"title":1282},{"VI":1283},"Shannon R. Hinson",{"url":1158,"publisher":1285,"properties":1307},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1286,"slug":10,"properties":1287,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1290,"manageAffiliations":1291,"indexDatabases":1292,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1288,"title":1289},{"VOID":13},{"EN":15},[],[],[1293,1300],{"id":82,"indexDatabase":1294,"url":95,"indexYears":96,"academicFieldIds":1299,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1295,"label":1296,"description":1297,"key":92,"publicationTags":1298,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":1301,"url":78,"indexYears":18,"academicFieldIds":1306,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":1302,"label":1303,"description":1304,"key":74,"publicationTags":1305,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":1308,"pages":1310},{"VOID":1309},"40",{"VOID":1311},"21-27","2013-02-01",2013,{"id":1315,"createTime":1316,"updateTime":1317,"relativeEntities":1318,"slug":1319,"properties":1320,"entityType":118,"verifyStatus":119,"verifyTime":1317,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1325,"fullTextUrl":18,"authors":1326,"publicationType":210,"publisherRelationship":1402,"citationCount":18,"citationInfo":18,"publishDate":1430,"publishYear":1431,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"7f033a68-278f-4ebd-81d5-decc1b567661","2023-12-01T05:02:40.798+00:00","2024-09-19T23:56:14.402+00:00",[],"Expression-of-intercellular-adhesion-molecule-1-and-lymphocyte-function-associated-antigen-3-on-human-thyroid-epithelial-cells-in-Graves-and-Hashimoto-s-diseases",{"title":1321,"doi":1323},{"EN":1322},"Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases",{"VOID":1324},"10.1016\u002Fs0896-8411(05)80039-3","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0896841105800393",[1327,1342,1354,1366,1378,1390],{"id":1328,"sortIndex":199,"researcher":18,"roles":1329,"affiliations":1330,"properties":1339},"0d40e5f4-ec5d-42cd-b6da-525820b83c79",[127],[1331],{"id":18,"sortIndex":19,"affiliation":1332,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1335,"slug":18,"properties":1336,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"56c05644-9d2e-4bdc-b365-226a95397206","2023-12-01T05:02:40.814+00:00",[],{"title":1337},{"VI":1338},"The Charing Cross Sunley Research Centre, 1 Lurgan Avenue, Hammersmith, London W6 8LW, UK",{"title":1340},{"VI":1341},"Colin Dayan",{"id":1343,"sortIndex":19,"researcher":18,"roles":1344,"affiliations":1345,"properties":1351},"528dc4cf-0d3b-46a4-b61f-05ee4834f413",[127],[1346],{"id":18,"sortIndex":19,"affiliation":1347,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1348,"slug":18,"properties":1349,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1350},{"VI":1338},{"title":1352},{"VI":1353},"Richard Q.H. Zheng",{"id":1355,"sortIndex":174,"researcher":18,"roles":1356,"affiliations":1357,"properties":1363},"aa232762-940a-4084-850d-f1ba0c7a91e2",[127],[1358],{"id":18,"sortIndex":19,"affiliation":1359,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1360,"slug":18,"properties":1361,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1362},{"VI":1338},{"title":1364},{"VI":1365},"Ravinder N. Maini",{"id":1367,"sortIndex":142,"researcher":18,"roles":1368,"affiliations":1369,"properties":1375},"66f5257d-b66e-4847-b635-689dacdb933a",[127],[1370],{"id":18,"sortIndex":19,"affiliation":1371,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1372,"slug":18,"properties":1373,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1374},{"VI":1338},{"title":1376},{"VI":1377},"Beatrix Grubeck-Loebenstein",{"id":1379,"sortIndex":125,"researcher":18,"roles":1380,"affiliations":1381,"properties":1387},"c1210948-a7c6-4c8f-8b33-c7b919d73dda",[127],[1382],{"id":18,"sortIndex":19,"affiliation":1383,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1384,"slug":18,"properties":1385,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1386},{"VI":1338},{"title":1388},{"VI":1389},"Marc Feldmann",{"id":1391,"sortIndex":158,"researcher":18,"roles":1392,"affiliations":1393,"properties":1399},"e11de7fe-4eb2-4bba-91c6-9f3cff221406",[127],[1394],{"id":18,"sortIndex":19,"affiliation":1395,"properties":18},{"id":1333,"createTime":1334,"updateTime":1334,"relativeEntities":1396,"slug":18,"properties":1397,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1398},{"VI":1338},{"title":1400},{"VI":1401},"Erika R. Abney",{"url":1325,"publisher":1403,"properties":1425},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1404,"slug":10,"properties":1405,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1408,"manageAffiliations":1409,"indexDatabases":1410,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1406,"title":1407},{"VOID":13},{"EN":15},[],[],[1411,1418],{"id":82,"indexDatabase":1412,"url":95,"indexYears":96,"academicFieldIds":1417,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1413,"label":1414,"description":1415,"key":92,"publicationTags":1416,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":1419,"url":78,"indexYears":18,"academicFieldIds":1424,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":1420,"label":1421,"description":1422,"key":74,"publicationTags":1423,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":1426,"pages":1428},{"VOID":1427},"3",{"VOID":1429},"727-736","1990-12-01",1990,{"id":1433,"createTime":1434,"updateTime":1435,"relativeEntities":1436,"slug":1437,"properties":1438,"entityType":118,"verifyStatus":119,"verifyTime":1445,"verifyNote":120,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1446,"fullTextUrl":18,"authors":1447,"publicationType":210,"publisherRelationship":1505,"citationCount":18,"citationInfo":18,"publishDate":1533,"publishYear":1534,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":241},"ebfc9bc2-916f-4d48-a3db-b1ce14d0f436","2024-01-05T02:28:31.887+00:00","2025-01-28T23:54:54.545+00:00",[],"Analysis-of-anti-idiotypic-antibodies-against-anti-microsomal-antibodies-in-patients-with-thyroid-autoimmunity",{"references":1439,"title":1441,"doi":1443},{"VOID":1440},"Banga, 1991, Immunological and molecular characteristics of the thyroid peroxidase autoantigen, Autoimmunity, 8, 335, 10.3109\u002F08916939109007642\nJansson, 1988, Postpartum thyroiditis, Ballière's Clin. Endocrinol. Metab, 2, 619, 10.1016\u002FS0950-351X(88)80056-9\nJerne, 1974, Towards a network theory of the immune system, Ann. Immunol. (Inst. Pasteur.), 125C, 373\nBurdette, 1987, Current concepts: immunology. Idiotypes and idiotypic networks, N. Engl. J. Med, 317, 219, 10.1056\u002FNEJM198707233170407\nAbdou, 1981, Network theory in autoimmunity: in vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus, J. Clin. Invest, 67, 1297, 10.1172\u002FJCI110158\nDwyer, 1983, Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients, Nature, 301, 611, 10.1038\u002F301611a0\nZanetti, 1981, Anti-idiotypic immunity and autoimmunity. I In vitro and in vivo effects of anti-idiotypic antibodies to spontaneously occurring autoantibodies to rat thyroglobulin, Eur. J. Immunol, 11, 187, 10.1002\u002Feji.1830110306\nRoubaty, 1990, Prevention of experimental autoimmune thyroiditis through the anti-idiotypic network, J. Immunol, 144, 2167, 10.4049\u002Fjimmunol.144.6.2167\nBaker, 1984, Production, isolation and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotropin receptor antibodies, J. Clin. Invest, 74, 488, 10.1172\u002FJCI111446\nKojima, 1986, Suppression of in vitro human antithyroglobulin antibody secretion by private and cross-reactive anti-idiotypic antibodies, Clin. Immunol. Immunopathol, 39, 337, 10.1016\u002F0090-1229(86)90097-8\nOchi, 1989, Anti-TSH antibodies in Graves' disease and their failure to interact with TSH receptor antibodies, Acta Endocrinol. (Copenh.), 120, 773, 10.1530\u002Facta.0.1200773\nNoh, 1989, Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease, J. Clin. Endocrinol. Metab, 68, 107, 10.1210\u002Fjcem-68-1-107\nRaines, 1985, Antithyrotropin antibodies in the sera of Graves' disease patients, J. Clin. Endocrinol. Metabol, 61, 217, 10.1210\u002Fjcem-61-2-217\nPaschke, 1990, Evidence for a role of anti-idiotypic antibodies in the induction of remission in Graves' disease, J. Autoimmunity, 3, 441, 10.1016\u002FS0896-8411(05)80011-3\nRossi, 1988, Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-hemophilic factor) are present in therapeutic polyspecific normal immunoglobulins, Clin. Exp. Immunol, 74, 311\nRossi, 1989, Anti-idiotypes against autoantibodies in pooled normal human polyspecific normal immunoglobulins, J. Immunol, 143, 4104, 10.4049\u002Fjimmunol.143.12.4104\nDietrich, 1990, Normal IgG for therapeutic use (IVIg) contain anti-idiotypic specificities against an immunodominant, disease associated, cross-reactive idiotype of human antithyroglobulin autoantibodies, J. Clin. Invest, 85, 620, 10.1172\u002FJCI114483\nvan Doorn, 1990, On the mechanism of high dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy, J. Neuroimmunol, 29, 57, 10.1016\u002F0165-5728(90)90147-F\nRossi, 1991, Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis, Clin. Exp. Immunol, 83, 298, 10.1111\u002Fj.1365-2249.1991.tb05631.x\nLiblau, 1991, Intravenous γ-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies, J. Clin. Immunol, 11, 128, 10.1007\u002FBF00918680\nFateh-Moghadam, 1984, High-dose intravenous gammaglobulin for myasthenia gravis, Lancet, i, 848, 10.1016\u002FS0140-6736(84)92294-3\nGajdos, 1987, High-dose intravenous gammaglobulin for myasthenia gravis: An alternative to plasma exchange?, Ann. N.Y. Acad. Sci, 505, 842, 10.1111\u002Fj.1749-6632.1987.tb51387.x\nJayne, 1991, Treatment of systemic vasculitis with pooled intravenous immunoglobulin, Lancet, 337, 1137, 10.1016\u002F0140-6736(91)92797-6\nRossi, 1989, Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation in human autoimmune responses, Immunol. Rev, 110, 135, 10.1111\u002Fj.1600-065X.1989.tb00031.x\nWeetman, 1984, Extra-thyroidal sites of autoantibody synthesis in Graves' disease, Clin. Exp. Immunol, 56, 330\nSultan, 1987, Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIII:C autoantibodies, 84, 828\nAdib, 1990, IgG autoantibody activity in normal mouse serum is controlled by IgM, J. Immunol, 145, 3807, 10.4049\u002Fjimmunol.145.11.3807",{"EN":1442},"Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity",{"VOID":1444},"10.1016\u002F0896-8411(92)90153-h","2025-01-28T23:54:54.544+00:00","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002F089684119290153H",[1448,1463,1478,1490],{"id":1449,"sortIndex":19,"researcher":18,"roles":1450,"affiliations":1451,"properties":1460},"c773feb1-ee7a-41a6-b6c5-b2f8ebb19cdd",[127],[1452],{"id":18,"sortIndex":19,"affiliation":1453,"properties":18},{"id":1454,"createTime":1455,"updateTime":1455,"relativeEntities":1456,"slug":18,"properties":1457,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"7b8df513-5dbd-4df6-8284-8617fd35605f","2024-02-13T08:29:59.772+00:00",[],{"title":1458},{"VI":1459},"Department of Medicine, University of Sheffield, Clinical Sciences Centre, Northern General Hospital, Sheffield S5 7AU, UK",{"title":1461},{"VI":1462},"N. Tandon",{"id":1464,"sortIndex":158,"researcher":18,"roles":1465,"affiliations":1466,"properties":1475},"b86fd13c-7a36-4bdd-b814-7a1e7fabe906",[127],[1467],{"id":18,"sortIndex":19,"affiliation":1468,"properties":18},{"id":1469,"createTime":1470,"updateTime":1470,"relativeEntities":1471,"slug":18,"properties":1472,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"2d0b4ba5-8f74-4dc5-a581-a26c7d6fb3a6","2023-12-27T05:09:57.370+00:00",[],{"title":1473},{"VI":1474},"Department of Medicine, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK",{"title":1476},{"VI":1477},"D.R.W. Jayne",{"id":1479,"sortIndex":199,"researcher":18,"roles":1480,"affiliations":1481,"properties":1487},"5870fb70-9902-471d-9ab1-232226246809",[127],[1482],{"id":18,"sortIndex":19,"affiliation":1483,"properties":18},{"id":1454,"createTime":1455,"updateTime":1455,"relativeEntities":1484,"slug":18,"properties":1485,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":1486},{"VI":1459},{"title":1488},{"VI":1489},"A.P. Weetman",{"id":1491,"sortIndex":142,"researcher":18,"roles":1492,"affiliations":1493,"properties":1502},"3a0e7b81-37e7-4c76-926e-48a20480e28c",[127],[1494],{"id":18,"sortIndex":19,"affiliation":1495,"properties":18},{"id":1496,"createTime":1497,"updateTime":1497,"relativeEntities":1498,"slug":18,"properties":1499,"entityType":47,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"6ac01c57-85e5-4444-93f1-dd8de0e207f4","2024-01-05T02:28:32.031+00:00",[],{"title":1500},{"VI":1501},"Department of Medicine, King's College Hospital Medical School, London SE5 8RX, UK",{"title":1503},{"VI":1504},"A.M. McGregor",{"url":1446,"publisher":1506,"properties":1528},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1507,"slug":10,"properties":1508,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1511,"manageAffiliations":1512,"indexDatabases":1513,"url":18,"thumbnailPath":18,"statistic":18,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1509,"title":1510},{"VOID":13},{"EN":15},[],[],[1514,1521],{"id":82,"indexDatabase":1515,"url":95,"indexYears":96,"academicFieldIds":1520,"indexDatabaseRanking":100},{"id":84,"createTime":85,"updateTime":86,"relativeEntities":1516,"label":1517,"description":1518,"key":92,"publicationTags":1519,"standard":18},[],{"EN":89,"VI":89},{"EN":89,"VI":91},[94],[98,99],{"id":63,"indexDatabase":1522,"url":78,"indexYears":18,"academicFieldIds":1527,"indexDatabaseRanking":18},{"id":65,"createTime":66,"updateTime":67,"relativeEntities":1523,"label":1524,"description":1525,"key":74,"publicationTags":1526,"standard":18},[],{"EN":70,"VI":70},{"VI":72,"EN":73},[76,77],[80],{"volume":1529,"pages":1531},{"VOID":1530},"5",{"VOID":1532},"557-570","1992-10-01",1992]